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Synthetic glucocorticoids (GCs) have been widely used for the 
treatment of autoimmune and inflammatory diseases and exert their 
actions through binding to the GC receptor (GR) (Ramamoorthy and 
Cidlowski, 2016). GR is a transcription factor (TF) belonging to the 
nuclear receptor (NR) superfamily that mediates a wide range of 
important physiological processes (Sacta et al., 2016). Upon ligand 
binding, GR translocates to the nucleus and exert its actions either 
through binding to DNA or interacting with other TFs. Direct 
transcriptional regulation by GR involves its binding to specific DNA 
regulatory sequences called GC responsive elements or GREs. 
 
For a long time, it was postulated that GR induced their anti-
inflammatory effects exclusively through transrepression by inhibiting 
known inflammatory pathways, including NF-B, AP-1 and MAPKs 
(Weikum et al., 2017). However, it is now accepted that transcriptional 
induction of several classic GRE-containing targets is also key for the 
anti-inflammatory actions of the GR (De Bosscher and Haegeman, 
2009). Continuous treatment or high doses of GCs may lead to 
unwanted side effects (skin atrophy), which may have a big impact in 
population (Sacta et al., 2016). Therefore it is important to understand 
the mechanisms by which GR regulates transcription in skin and their 
impact on the therapeutic and adverse effects of GCs. 
 
In part I of this dissertation, we studied the regulation of GC-
induced leucine zipper (Gilz/Tsc22d3) and Zinc Finger Protein 
36/Tristetraprolin (Zfp36/Ttp), two primary transcriptional GR targets 
containing GRE binding motifs, in epidermal keratinocytes. These and 
other GC-targets were previously identified in our laboratory by GR 
ChIP-seq assays in which GRE, Krüppel-like factor (KLF), and AP-1 
were the most overrepresented binding motifs. Given the relevance of 
GR and Krüppel-like factor 4 (KLF4) in skin, we have analysed the 
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functional interactions between these TFs and their impact on 
Gilz/Tsc22d3 and Zfp36/Ttp gene expression. 
 
Loss of function experiments of GR and KLF4 demonstrated total 
GR but partial KLF4 requirement for full gene induction in response to 
dexamethasone (Dex). In calcium-induced terminally differentiatied 
keratinocytes, GR and KLF4 protein expression increased concomitant 
with Gilz/Tsc22d3 and Zfp36/Ttp up-regulation. However, GR-deficient 
cells failed to differentiate or fully induce Gilz, Zfp36 and Klf4 correlating 
with an augmented expression of Trp63, a known transcriptional 
repressor of KLF4 which is epithelium-specific. The identified 
transcriptional cooperation between GR and KLF4 may determine cell-
type specific regulation and have implications for developing therapies 
for skin diseases. 
 
In part II of this dissertation, we have investigated GILZ, which has 
been shown to act as anti-inflammatory mediator in several cell types 
similar to GCs but without producing the GC-associated side effects. In 
contrast, little is known about the role of GILZ in skin function. Thus, we 
decided to study consequences of GILZ overexpression in psoriasis, an 
autoimmune inflammatory skin disease, where keratinocytes and 
immune cells play an important role. For this purpose we used an 
Imiquimod (IMQ)-induced psoriasis model in mice with generalized 
overexpression of GILZ (GILZ-Tg). Unexpectedly, GILZ-Tg showed 
more susceptibility to the IMQ-induced psoriasis, displaying more 
severe skin alterations shown by histological (increased epidermal 
hyperplasia and parakeratosis), and biochemical analysis (increased 
cytokine levels in serum and skin). Importantly, these alterations 
correlated with skin-specific overactivation of the TGF-β/SMAD 
signaling, which was recapitulated in cultured keratinocytes. Overall, 
these findings show that GILZ acts as a pro-inflammatory protein in skin 
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in an IMQ-induced model of psoriasis and thus caution is advised in its 
therapeutic use.  
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Los glucocorticoides (GCs) sintéticos han sido ampliamente 
utilizados para el tratamiento de las enfermedades autoinmunes e 
inflamatorias y ejercen sus acciones mediante la unión al receptor de 
GCs (GR en inglés) (Ramamoorthy y Cidlowski, 2016). GR es un factor 
de transcripción (TF en inglés) que pertenece a la superfamilia de 
receptores nucleares que media importantes procesos fisiológicos 
(Sacta et al., 2016). Tras la unión del ligando, GR se transloca al núcleo 
y ejerce sus acciones mediante la unión a DNA o interaccionando con 
otros factores de transcripción. La regulación transcripcional directa por 
GR implica su unión a secuencias reguladoras de ADN específicas 
llamadas elementos de respuesta a GC o GREs. 
 
Durante mucho tiempo, se postuló que GR inducía sus efectos 
antiinflamatorios exclusivamente a través de la transrepresión 
mediante la inhibición de las vías inflamatorias conocidas, incluyendo 
NF-B, AP-1 y MAPKs (Weikum et al., 2017). Sin embargo, ahora se 
acepta que la inducción transcripcional de varias dianas clásicas que 
contienen GRE también es clave para las acciones anti-inflamatorias 
de GR (De Bosscher and Haegeman, 2009). El tratamiento continuo o 
altas dosis de GCs pueden producir efectos secundarios no deseados 
(atrofia de la piel), lo que puede tener un gran impacto en la población 
(Sacta et al., 2016). Por lo tanto, es importante comprender los 
mecanismos por los que GR regula la transcripción en la piel y su 
impacto en los efectos terapéuticos y adversos de los GCs. 
 
En la parte I de esta tesis se estudió la regulación de GC-induced 
leucine zipper (Gilz/Tsc22d3) y Zinc Finger Protein 36/Tristetraprolin 
(Zfp36/Ttp), dos dianas transcripcionales primarias de GR que 
contienen motivos de unión GRE, en queratinocitos epidérmicos. Éstas 
y otras dianas de GCs se han identificado previamente en el laboratorio 
mediante ensayos GR ChIP-seq en los que GRE, Krüppel-like factor 
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(KLF), y AP-1 eran los motivos de unión más sobre-representados. 
Dada la relevancia de GR y KLF4 en la piel, hemos analizado las 
interacciones funcionales entre estos factores de transcripción y su 
impacto en la expresión de los genes Gilz/Tsc22d3 y Zfp36/Ttp. 
 
Los experimentos de pérdida de función de GR y KLF4 mostraron 
un requisito total de GR pero parcial de KLF4 para la completa 
inducción de genes en respuesta a dexametasona (Dex). En los 
queratinocitos terminalmente diferenciados inducidos por calcio, la 
expresión de la proteína GR y KLF4 aumentó coincidiendo con el 
aumento de Gilz/Tsc22d3 y Zfp36/Ttp. Sin embargo, las células 
deficientes en GR no lograron diferenciar o inducir completamente Gilz, 
Zfp36 y Klf4, correlacionando con el aumento de la expresión de Trp63, 
un conocido represor transcripcional de KLF4 que es específico del 
epitelio. La cooperación transcripcional identificada entre GR y KLF4 
puede que determine la regulación específica del tipo celular y tiene 
implicaciones para el desarrollo de terapias para enfermedades de la 
piel. 
 
En la parte II de esta tesis, hemos investigado GILZ, que se ha 
demostrado que actúa como mediador antiinflamatorio en varios tipos 
celulares de manera similar a los GCs pero sin producir los efectos 
secundarios asociados a GC. Por el contrario, poco se sabe sobre el 
papel de GILZ en la función de la piel. Por tanto, decidimos estudiar las 
consecuencias de la sobreexpresión de GILZ en la psoriasis, una 
enfermedad autoinmune inflamatoria de la piel, en la que los 
queratinocitos y las células inmunitarias desempeñan un papel 
importante. Para ello, utilizamos un modelo de psoriasis inducido por 
Imiquimod (IMQ) en ratones con sobreexpresión generalizada de GILZ 
(GILZ-Tg). Inesperadamente, GILZ-Tg mostró más susceptibilidad a la 
psoriasis inducida por IMQ, mostrando alteraciones cutáneas más 
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severas mostradas mediante histología (aumento de la hiperplasia 
epidérmica y paraqueratosis) y análisis bioquímico (niveles de 
citoquinas en suero y piel). Es importante destacar que estas 
alteraciones se correlacionaron con la sobreactivación de la 
señalización TGF-β/SMAD específica en la piel, que se recapituló en 
queratinocitos en cultivo. En general, estos hallazgos muestran que la 
GILZ actúa como una proteína pro-inflamatoria en la piel en un modelo 
de psoriasis inducido por IMQ y por lo tanto conviene tener precaución 
a la hora de considerar su uso terapéutico. 
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1. The skin 
1.1. Skin structure and function 
Skin is the largest and outermost organ of the body, which not only 
forms a physical barrier between the internal organs and the 
surrounding environment but it also has an active role in maintaining 
organism homeostasis. Skin has a pivotal role in protecting the body 
from the harmful microbes, chemical agents and acts as an insulator for 
the body to maintain the internal body temperature. Skin is a part of the 
integumentary system, which also comprises hair and nails (Fuchs and 
Horsley, 2008; Menon, 2002). 
The physiology of the skin is complex and made up of different 
layers, namely from inner to outside hypodermis, dermis and epidermis. 
 
Figure 1. Organization of the skin. Skin contains three major layers namely 
hypodermis, dermis and epidermis. Hypodermis consists of the lowermost layer 
and is comprised of adipocytes, fibroblasts and macrophages, as well as 
connective tissue and elastine. Dermis is the middle layer consists of elastic 
fibers, collagen, lymphatic and blood vessels, sensory structures, as well as 
hair follicles and sebaceous and sweat glands and fibroblasts. Finally, 
epidermis, the outermost layer of the skin, includes mainly keratinocytes and 
melanocytes. Appendages: hair follicles and sebaceous glands from dermis. 
This image has been captured from http://www.clinuvel.com/  
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Hypodermis is the inner layer of the skin and lies beneath the 
dermis. It is mostly constituted by adipocytes, fibroblasts and 
macrophages, connective tissue and elastin (Figure 1). 
 
The dermis is derived from mesoderm and contains elastic fibers, 
collagen, lymphatic and blood vessels, as well as sensory structures 
(Fuchs and Raghavan, 2002). The major cell type is the fibroblast. Hair 
follicles and sebaceous and sweat glands are appendages localized in 
this layer, although they are epidermal derivatives. Dermis is connected 
to the next outer layer by the basement membrane and provides tensile 
strength and elasticity to the skin (Figure 1). 
 
The epidermis, the outermost layer of the skin, is derived from the 
ectoderm and is mainly composed of keratinocytes. Other cell types, 
such as melanocytes and antigen-presenting cells termed Langerhans 
cells are also present. Epidermis is composed of different layers that 
are explained below (Fuchs and Raghavan, 2002; Figure 1). 
1.2. Epidermal structure and formation  
The epidermis is a self-renewing stratified and keratinized 
epithelium, which consists of five different layers of cells known as the 
stratum basale or basal layer, stratum spinosum, stratum granulosum, 
stratum lucidum (only present in human palms and soles) and stratum 
corneum (Fuchs and Horsley, 2008; Figure 2). The epidermis is 
constantly renewing, as cells of the outer layers are continuously shed 
and replaced by the inner cells, which move up to the surface. The 
keratinocytes present in the basal layer of the epidermis have the ability 
to divide continuously. The newly formed cells migrate towards the 
more superficial layers of the skin and start the differentiation. In the 
stratum granulosum keratinocytes continue to flatten, lose their nuclei 
and their cytoplasm looks granular. Finally in the stratum corneum, the 
Introduction 
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exterior layer of the epidermis, keratinocytes become non-viable 
cornified cells (flattened dead cells filled with keratin filaments and 
water), namely corneocytes. These cells are surrounded by lipid layers 
and by a protein envelope filled with water-retaining keratin proteins 
(Fuchs and Horsley, 2008). The stratum corneum provides the first 
barrier against external insults (Fuchs and Horsley, 2008). It is also 
composed of structural proteins, including involucrin, loricrin and small 
proline-rich repeat proteins (SPRRs), all being part of the epidermal 
differentiation complex encoded by genes localized on human 
chromosome 1q21 (Jackson et al., 2005).  
 
Figure 2.  Epidermis structure is formed by different layers named stratum 
basale or basal layer, stratum spinosum, stratum granulosum and stratum 
corneum. This image has been captured from http://www.clinuvel.com/  
 
There is an extracellular calcium gradient in the epidermis, which 
is a very important factor in the regulation of epidermal differentiation 
and cell-cell adhesion. In fact, the addition of calcium to in vitro primary 
keratinocytes recapitulates the in vivo differentiation by inducing 
morphological changes and formation of cell-cell contacts along with 
the expression of differentiation markers, such as SPRRs and loricrin, 
among others (Hennings et al., 1980; Sen et al., 2008). 
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1.3. Skin pathologies 
Immune and inflammatory responses protect us from external 
pathogens. However, when the skin protection mechanisms fail or are 
not sufficient, humans can develop distinct pathologies. Inflammation is 
a necessary part of the response, but it is unhealthy when it becomes 
chronic. 
 
Skin can be affected by external insults such as UV radiation, 
microbes, mechanical damage and chemicals. For a normal epidermal 
function it is required a tight control of keratinocyte proliferation, 
differentiation and death. A dysregulation among these processes may 
lead to an aberrant barrier function and subsequently to skin diseases, 
such as atopic dermatitis, psoriasis, ichthyosis vulgaris, etc (Fuchs and 
Raghavan, 2002; Bernard et al., 2012; Sen et al., 2012 ).  
2. Psoriasis 
2.1. Etiology and pathogenesis   
Psoriasis is a common inflammatory and autoimmune skin 
disease, which implies impaired barrier function of the skin due to 
hyperproliferation and abnormal differentiation of epidermal 
keratinocytes and massive infiltration of leukocytes (Kim and Krueger, 
2017). Psoriasis has a complex etiology and is distributed globally, 
affecting 2-3% worldwide (Kanemaru et al., 2015). 
 
Psoriasis onset is common between the ages of 18 and 39 (Greb, 
et al., 2016), but it can appear at any age. Many of the individuals 
suffering from psoriasis have also associated co-morbidities, including 
metabolic syndrome, hypertension, diabetes, obesity, depression, 
Introduction 
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inflammatory bowel disease and arthritis impairing quality of life and 
work productivity significantly (Johnson-Huang et al., 2012).  
 
Although etiology of psoriasis is still not well established, psoriasis 
has been shown to be caused by genetic and environmental factors. 
Among the genetic factors we can find genes that are up-regulated in 
psoriasis and encode S100A8 and A9 expressed by keratinocytes from 
the granular layer and genes associated with adaptive and innate 
immunity such as β-defensins, TNF-α signaling pathway, the IL-
23/Th17–related genes, STAT3 and C-JUN/JUNB (Johnson-Huang 
et al., 2012; Wagner et al., 2012).  
 
Environmental factors can trigger the onset or exacerbate the 
psoriasis. These factors include smoking, alcohol consumption, 
obesity, medications (imiquimod (IMQ), beta blockers), infections, as 
well as stress (Kanemaru et al., 2015; Figure 3).  
 
Figure 3. Risk factors associated with the development of psoriasis. 
Genetic and environmental factors are involved in the onset or exacerbation of 
psoriasis.  
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There are different types of psoriasis, termed as psoriasis vulgaris, 
guttate psoriasis, among others (Boehncke and Schön, 2015). In fact, 
up to 30% of individuals suffering from psoriasis may develop psoriatic 
arthritis (Johnson-Huang et al., 2012). The most common clinical 
variant is psoriasis vulgaris, characterized by variable width of 
erythematous lesions covered by silvery-white scales over the whole 
body, which can cause pain and itch to the patient. 
  
Figure 4. Clinical features of psoriasis vulgaris disease. Typical flaky white 
scale can appear in the whole body. These images show scales in legs and 
trunk. From Boehncke and Schön, 2015. 
Psoriasis is characterized by the following features (Wagner et al., 
2010; Figure 5): 
- Epidermal hyperplasia driven by hyperproliferation of 
keratinocytes, thickening of the stratum corneum 
(hyperkeratosis) and elongated epidermal invaginations 
termed as rete-ridges. 
- Impaired keratinocyte differentiation and parakeratosis. 
- Absence or reduction of granular layer. 
- Dermal infiltration of inflammatory immune cells. 
- Increased dermal vascularity 
Introduction 
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Figure 5. Structure of human healthy skin compared to psoriatic skin. The 
image shows all the microscopic features of healthy and psoriatic human skin. 
Adapted from Wagner et al., 2010. 
2.2. Immunopathogenesis: pathways implicated in 
psoriasis 
 
Although pathogenesis is still not fully understood, certain immune 
cells from both the innate and adaptive immune system (neutrophils, 
dendritic cells, T cells), as well as epithelial cells (epidermal 
keratinocytes) have been found to be involved in the development and 
maintenance of psoriasis by producing cytokines (IL-6, IL-17A, IL-17F, 
IL-22, IL-23 and TNF-α) (Johnson-Huang et al., 2012). 
 
Toll-like receptors (TLRs) are part of the pattern recognition 
receptors and belong to the IL-1 Receptor/TLR superfamily, which is 
composed of 9 members (TLR1-TLR9), each recognizing different 
pathogens.There are transmembrane TLR in the cell membrane or 
endosomal compartments. TLR7 and 8 are the only TLRs expressed 
on the X chromosome and they can detect both self- and non-self-
nucleic acids. Several autoimmune disorders (psoriasis, systemic lupus 
Introduction 
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erythematosus, rheumatoid arthritis, or systemic sclerosis) are 
associated with abnormal sensing of self-nucleic acids by TLR7, 8, or 
9. TLR recognize bacteria and virus after they have crossed the barriers 
of the innate immune system, being very important in the initiation of 
the inflammatory response and in the development of adaptive immune 
responses, including the stimulation of naïve T cells (Flutter and Nestle, 
2013). 
In psoriasis, upon external stimuli, dendritic cells expressing the 
TLR 7/8/9, mature and migrate to the draining lymph nodes where they 
present the processed peptides (antigens) to naïve T cells and release 
cytokines such as IL-23, IL-6, IL-12, TNF-α and Interferon (IFN)-γ, 
which induce the T cell expansion and differentiation into different 
subsets of T cells. Then, these cells migrate back to the epidermis and 
dermis and interact with other immune cells (dendritic cells, mast cells, 
macrophages, and neutrophils), leading to a continuous proliferation of 
keratinocytes and T cells recruitment (Kim and Krueger, 2017). 
Among the immune cells, T cell population have been shown to 
play a primary role in psoriasis since their reduction was associated with 
an improvement of psoriasis symptoms (Kim and Krueger, 2017). There 
are several types of T cells in lesional psoriatic skin, which are termed 
depending on the cytokines they produce: Th1, Th17, Th22 and Treg. 
The Th17 cells are driven by IL-1β, IL-6, transforming growth factor-β 
(TGF-β), and IL-23 and produce IL-22 and IL-17, a potent inducer of 
neutrophil activation and recruitment, in response to bacterial and 
fungal pathogens.  
2.2.1. IL-23/Th17 axis 
The IL-23/Th17 axis is involved in the pathogenesis of various 
inflammatory diseases, including rheumatoid arthritis, inflammatory 
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bowel disease and psoriasis (Han et al., 2012). The main components 
that constitute this axis, IL-23, IL-22, IL-17, are up-regulated in psoriasis 
patients (Wolk et al., 2006; Johnson-Huang et al., 2012). Skin dendritic 
cells secrete IL-23, which stimulates Th17 cells to produce pro-
inflammatory mediators, including IL-17A, IL-17F, and IL-22. Then, 
these mediators activate keratinocytes and induce their 
hyperproliferation, subsequently producing pro-inflammatory cytokines, 
chemokines, and antimicrobial peptides, leading to further recruitment 
and activation of immune cells in the inflamed skin, finally amplificating 
the immune response. Although IL-1β, IL-6 and TGF-β produce the 
differentiation of Th17 cells, IL-23 is necessary for stabilization, survival 
and proliferation of the Th17 cell type (Johnson-Huang et al., 2012).  
IL-22 is the strongest activator of keratinocytes and induces 
epidermal proliferation contributing to epidermis thickening. IL-22 can 
be produced by different sources, including natural killer, innate 
lymphoid cells, and adaptive CD4+ or CD8+T cells. The main targets 
of IL-22 are intestinal epithelial cells and skin since they express the 
IL-22R. IL-22 signaling results in the activation of pro-inflammatory 
signaling pathways, such as STAT3 and antimicrobial peptides                
β-defensin 2, β-defensin 3, and psoriasin (S100A7) in human 
keratinocytes, among others (Wolk et al., 2006).  
Among the different subtypes that constitutes the IL-17 family,          
IL-17A and IL-17F have been found up-regulated in psoriasis and are 
involved in the pathogenesis of inflammation. IL-17F is the most closely 
related to IL-17A with approximately 44% aa sequence homology.             
IL-17 is involved in the microabscess formation in the IMQ-induced 
psoriasis model and induces keratinocyte proliferation while inhibits 
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their differentiation, contributing to the epidermal hyperplasia (Ha et al., 
2014).  
 
Figure 6. Scheme of pathways implicated in psoriasis. Immune cells are 
stimulated and secrete cytokines (IL-23), which activates the T cell subsets 
which consequently activate keratinocytes through IL-17 and IL-22 
production. This cascade results in activation of STAT3 pathway and 
favours the recruitment of neutrophils and the production of antimicrobial 
peptides.  
2.3. Therapy  
Although no definitive cure for psoriasis has been discovered, 
some treatments alleviate the symptoms of this disease and improve 
life conditions for the psoriasis patients. 
2.3.1. Topical treatment  
Depending on the degree of psoriasis severity, different treatments 
are recommended. The main therapies are psoralen and ultraviolet A 
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(PUVA) photochemotherapy, topical treatment with corticosteroids, 
retinoids, immunosuppressants, vitamin D analogs, and biological 
therapies. 
Both corticosteroids and vitamin D analogs act by binding and 
activating hormone receptors that belong to the nuclear hormone 
receptor superfamily. In fact, these intracellular receptors act as ligand-
dependent TFs and are the most frequently targets in the treatment of 
inflammatory pathologies, including skin diseases (Boehncke and 
Schön, 2015). 
Corticosteroids are the most and commonly used as topical 
treatment for psoriasis and for all the grades of this disease, either as 
monotherapy or in combination with systemic treatment. Their 
therapeutic response is mediated by vasoconstriction, anti-
inflammatory and immunosuppressive effects; however, continuous 
treatments and/or high doses often cause severe systemic side effects, 
including hypertension, osteoporosis, cataracts, glaucoma, and 
diabetes, among others (Menter et al., 2009). Regarding vitamin D 
analogs, they regulate genes involved in epidermal proliferation, 
inflammation, and keratinization. However, this treatment is also 
accompanied by side effects, as they can produce skin irritation and 
photosensitivity (Menter et al., 2009). 
2.3.2. Systemic treatment  
Systemic treatments involve the administration of drugs either 
orally or by injection. Specific biologic compounds were designed after 
the observation of improvement of psoriasis patients under 
immunosuppressive agents. General anti-psoriatic therapies target pro-
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inflammatory pathways, which involve the use of antibodies, soluble 
cytokine receptors, and fusion proteins.  
The first biological drugs for the treatment of psoriasis vulgaris 
were developed to target TNF-α, an important inflammatory cytokine 
belonging to the Th1-derived cytokines, which exerts pleiotropic effects 
and regulates inflammation and immune system (Raychaudhuri and 
Raychaudhuri, 2009). However, as TNF-α is a major cytokine for the 
host defense, blocking this cytokine may cause side effects such as 
persistent fatigue and more severity of infections, among others.  
The IL-23 and IL-17 cytokines are important mediators of psoriasis 
and play a major role in the immunopathogenesis of psoriasis 
(Johnson-Huang et al., 2012). For this reason, the members of this axis 
have been considered as a potential target for the psoriasis treatment 
(Han et al., 2012). Several inhibitors of IL-23 and IL-17 have been 
recently tested in psoriasis patients. For instance, Ustekinumab, a 
monoclonal antibody that targets both IL-12 and IL-23 is used to treat 
moderate-to-severe psoriasis and results in the inhibition of the 
following downstream signaling pathway in T cells. Similarly, 
secukinumab and ixekizumab are also monoclonal antibodies that are 
approved for the treatment of the psoriasis, that specifically bind to the 
IL-17. Additionally, monoclonal antibodies that are able to target IL-17 
receptors were also developed. 
2.4. Experimental models of psoriasis 
Psoriasis is a complex immunopathological response. To 
understand the molecular events underlying this disease several in vitro 
and in vivo models have been generated. Most of the models 
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recapitulate critical events that take place in psoriasis patients. In vitro 
models include cultured psoriatic keratinocytes, whereas in vivo models 
include mice and humanized mice. Also, chemical induced models, 
including the IMQ-induced psoriasis mouse model are widely used to 
study psoriasis phenotypes in mice. 
2.4.1. In vitro models of psoriasis  
In vitro models of psoriasis can be either simple (culture of psoriatic 
keratinocytes alone or including additional cell types) or complex 
(reconstituted human epidermis). In this model that resembles a 3D 
structure, epidermal keratinocytes are obtained from individuals, and 
grown at the air-liquid interface to differentiate and stratify simulating 
the morphology of normal stratified epidermis. Under a mix of IL-22, 
TNF-α, and IL-17 conditions, displays histological features and up-
regulation of the characteristic molecules of psoriasis, including S100a7 
and β-defensin2 (Bernard et al., 2012).  
 
2.4.2. In vivo models of psoriasis 
In 1996, Wrone-Smith and colleagues designed a mouse model 
for psoriasis consisting of the humanized xenotransplantation onto 
immunosuppressed mice (Wrone-Smith and Nickoloff, 1996) where 
keratome skin samples from healthy volunteers and psoriasis patients 
were grafted onto severe combined immunodeficient (SCID) mice. Mice 
carrying the human psoriatic skin displayed all the psoriasis histological 
abnormalities. This model showed that injecting the autologous 
psoriatic T cells into xenotransplanted normal skin from the same 
patient could induce psoriasis. 
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To study psoriasis in vivo, several knockout (KO) and transgenic 
mouse models have been generated. Among them, K5 (latent) TGF-β1 
mice, which express TGF-β1 in the epidermis using a keratin 5 
promoter. TGF-β1 is a potent keratinocyte growth inhibitor whose 
overexpression was reported to display unexpected features 
resembling psoriasis, including the histological parameters, as well as 
the immune increased infiltrates in the skin (Li et al., 2004). 
Another example of a transgenic mouse model for psoriasis is K5-
STAT3C mice (Sano et al., 2005), where keratinocytes expressed a 
constitutively (C) active form of STAT3. STAT3 is known to be up-
regulated in human psoriatic lesions. By the 2 weeks of age, K5-
STAT3C transgenic mice developed features found in psoriasis, 
including loss of granular layer, keratinocyte hyperproliferation, 
alteration in differentiation (parakeratosis), and leukocyte infiltrates, 
among others.  
Also, mice with inducible, conditional deletion of both JUNB and c-
JUN in basal keratinocytes (K5-JUNB/c-JUN) displayed the hallmarks 
of psoriasis at the 2 months of age despite single conditional KO mice 
for JUNB or c-JUN did not display any features of psoriasis (Zenz et al., 
2005). Both c-JUN and JUNB are components of the Activator Protein 
(AP)-1 family. It is important to note that K5-JUNB/c-JUN mice also 
developed arthritis, constituting a good model for psoriatic arthritis. 
2.4.2.1. Imiquimod-induced psoriasis mouse model  
IMQ is a known drug prescribed under a cream formulation called 
Aldara® and widely used to treat condyloma acuminata, solar keratosis 
and basal cell carcinoma by topical application on skin. In the past years 
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the application of Aldara in human patients for the treatment of the 
aforementioned skin alterations was shown to trigger lesions on skin 
that resembled psoriasis plaques (Fanti et al., 2006). Based on this fact, 
in 2009, van der Fits and colleagues tested the daily topical application 
of Aldara cream on the shaved back mouse dorsal skin and revealed 
its power to induce psoriasis-like features. These alterations included 
all the clinical and histopathological features of human psoriasis in 
respect to erythema, scaling and induration and epidermal thickening, 
parakeratosis, neoangiogenesis and infiltration of immune cells in the 
dermis (Van der Fits et al., 2009). The major biologic effects of IMQ are 
mediated through agonistic activity towards TLR7. 
Aldara can also induce psoriasis-like skin inflammation through the 
IL-23/Th17 axis, which is a pivotal signaling in human psoriasis (Han et 
al., 2012; Van der Fits et al., 2009). Taken all together, this mouse 
model fulfils many of the necessary criteria to establish an ideal 
psoriasis mouse model (Van der Fits et al., 2009). Furthermore, drugs 
to ameliorate features of IMQ-induced psoriasis can be tested, which 
explains that this is one of the best mouse models nowadays for 
studying the mechanisms of this disease (Van der Fits et al., 2009).  
3. Glucocorticoids  
Glucocorticoids (GCs) are endogenous steroid hormones 
responsible for the regulation of many physiological functions 
(metabolism, embryonic development, stress response, inflammation, 
immune response, and cell proliferation, differentiation) (Sacta et al., 
2016). GCs are released in response to physical injury or psychological 
stress. The anti-inflammatory and immunomodulatory activities of GCs 
were discovered in the late 1940s and since then GCs have been used 
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for the treatment of various diseases, including asthma, hematological 
diseases, multiple sclerosis, rheumatoid arthritis, as well as psoriasis 
and atopic dermatitis, to name a few (Sacta et al., 2016). 
 
Besides the therapeutic effects of GCs, long-term use or high 
concentrations of GCs may cause adverse effects, such as 
hypertension, diabetes, muscle atrophy, and osteoporosis and 
specifically in the skin, atrophy and retarded wound healing (Sacta et 
al., 2016). 
 
3.1. Systemic GC production. The hypothalamic-
pituitary-adrenal (HPA) axis 
 
Systemic GCs are produced and controlled by the hypothalamic-
pituitary-adrenal (HPA) axis. Upon an environmental (flight/fight, abrupt 
temperature changes, etc.) or physiological stressors, the 
hypothalamus secretes corticotropin-releasing hormone (CRH), which 
stimulates the pituitary to release adrenocorticotropic hormone (ACTH), 
which subsequently induces the production of mineralocorticoids and 
glucocorticoids by the adrenal cortex (in the glomerulosa and 
fasciculate of the adrenal gland, respectively). This hormone cascade 
results in an adaptive response to deal with stress generated by the 
environmental or physiological stressor. Once the stress has finished 
levels of GCs decrease rapidly (Oakley and Cidlowski, 2013). The 
levels of GCs are regulated by a negative feedback since elevated 
concentration of GCs inhibits their production (Sacta et al., 2016; 
Figure 7).  
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Figure 7. Representation of the function of the HPA axis upon stress. From 
Oakley and Cidlowski, 2013. CRH: corticotropin-releasing hormone; ACTH: 
adrenocorticotropic hormone. 
Cortisol is the most predominant GC in humans, while 
corticosterone is the most predominant in rodents. 
Besides external stressors, the release of GCs is under control of 
the circadian clock, which is maintained by the HPA axis, reaching a 
daily peak time in the morning for humans and evening for rodents, 
correlating with their respective highest activity. Continuous or repeated 
exposition to the stress develops constant high GC levels and 
deregulation of the negative feedback mediated by the HPA axis, what 
can lead to stress-induced pathologies.  
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Further studies discovered that GCs were synthesized not only in 
the adrenals, but also in other peripheral tissues, including lungs, skin, 
etc. Particularly, the skin expresses all elements of the HPA axis 
including CRH, ACTH, and GCs, as well as steroidogenic enzymes 
required for GC synthesis (Slominski et al., 2013).  
Keratinocytes and fibroblasts also express the enzymes 11β-
hydroxysteroid dehydrogenase (11βHSD)1 and 11βHSD2, which 
transform inactive cortisone/11-dehydrocorticosterone to active 
cortisol/corticosterone and vice versa. 11βHSD1 expression is lower in 
psoriatic lesions relative to unlesioned skin (Slominski et al., 2013). 
4. Glucocorticoid receptor (GR) 
 
GC effects are mediated by the protein named GC receptor (GR), 
encoded by the gene NR3C1, which is an important TF that belongs to 
the NR superfamily and is virtually expressed in all vertebrate tissues. 
 
GR, formed by 9 exons and located on chromosome 5, exists in 
various splicing variants, among which GRα and GRβ are the most 
important and are generated from the alternative splicing at exon 9 of 
primary GR transcript. Importantly, only GRα can bind ligand although 
alternative roles have proposed for GRβ in different tissues, including a 
dominant negative function upon GRα (Weikum et al., 2017).  
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4.1. Structure of GR 
GR is constituted by three main domains (Weikum et al., 2017; 
Figure 8): 
In human GR, the N-terminal domain (NTD), constituted by 421 
amino acids, comprises the ligand-independent activation function 1 
(AF-1). This part is important for maximal transcriptional activation of 
the receptor since it interacts with coactivators, chromatin modulators, 
and the basal transcriptional machinery and activates target genes 
independently of ligand. It is the main site for the posttranslational 
modifications. This domain is the least conserved among all the 
members of the NR superfamily. 
The central DNA binding domain (DBD) (residues 422 to 486) is 
the most conserved among the NRs and is composed of two highly 
conserved zinc fingers that mediate the binding of the receptor to DNA 
sequences named GC response elements (GREs), as well as protein-
protein interactions. The first zinc finger contains the amino acids 
implicated in the GR binding to GRE, termed P box, whereas the 
second zinc finger contains the D box that drives the GR binding 
stabilization and homodimerization (Weikum et al., 2017).  
The DBD is connected to the C-terminally located ligand binding 
domain (LBD) by the hinge region (residues 487 to 526), which 
provides flexibility/elasticity to GR dimers, promoting GR DNA binding.  
The LBD (residues 527 to 777) binds to GCs. It consists of the 
hydrophobic ligand-dependent activation function 2 (AF-2), which is 
formed by 12 α-helices and 4 β-sheets and facilitates the interaction, in 
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a ligand-dependent fashion, with cochaperone proteins, coregulators, 
and other transcriptional machinery. Nuclear localization signals in both 
the DBD and LBD mediate GR nuclear translocation (Oakley and 
Cidlowski, 2013). 
Post-translational modifications (such as ubiquitination, 
acetylation, and phosphorylation) can regulate GR functions and 
influence the binding of GR to the DNA. In fact, GR phosphorylation 
may lead to a selective occupation of promoters on GR target genes 
and also regulate turnover, cofactor interaction, receptor stability, etc, 
ultimately influencing the role of GR in pathophysiology (Oakley and 
Cidlowski, 2013). GR can be phosphorylated by mitogen-activated 
protein kinase (MAPKs), cyclin-dependent kinases, c-Jun N-terminal 
kinases (JNK), etc, on 7 residues located in the NTD, which can alter 
the GR transcriptional activity. Specifically, the phosphorylation on 
serine 211 increases the GR transcriptional activity (Oakley and 
Cidlowski, 2013). 
 
 
 
Figure 8. Structure of GR protein and post-translational modifications. 
The different domains of the structure of GR are depicted. The figure shows the 
sites of post-translational modification: phosphorylation (P), sumoylation (S), 
ubiquitination (U), and acetylation (A). From Oakley and Cidlowski, 2013).  
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4.2. Mechanisms of GR action 
 
GCs binding to the GR can lead to the biological response through 
genomic or non-genomic actions.  
 
The genomic actions are mediated through both DNA-binding-
dependent and DNA-binding-independent mechanisms of GR. The first 
mechanism requires ligand-induced dimerization of GR and binding to 
specific DNA sequences to induce or repress gene expression, while 
the latter consists in the interaction with other TFs, such as nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-B) and     
AP-1 (Weikum et al., 2017).  
 
In the absence of ligand, monomeric GR is normally localized in 
the cytoplasm of the cell in a complex with chaperone proteins 
containing heat shock protein (HSP) 90, HSP70, and other factors, so 
this interaction promotes high-affinity hormone binding and inactivates 
nuclear localization and DNA binding. Upon ligand binding to the 
receptor, GR is phosphorylated, changes its conformation, translocates 
to the nucleus, where it binds to the DNA and forms complexes with 
other transcription and co-regulatory factors to regulate gene 
expression (Weikum et al., 2017).  
 
GR can bind to different DNA regulatory sequences: a) specific 
DNA sequences called GREs, consisting in a palindromic sequence 
comprised of 2 half sites (the canonical DNA sequence 
AGAACAnnnTGTTCT, where n is any nucleotide). GR binds to GREs 
as an homodimer often resulting in gene induction (Weikum et al., 
2017); b) simple GREs (CTCCnnGGAGA), where GR binding often 
results in the suppression of gene expression (CRH, 
Proopiomelanocortin); c) inverted repeated IRnGRE, which results in 
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gene repression as reported for numerous genes including thymic 
stromal lymphopoietin (Tslp), which is repressed through binding of GC-
activated GR in a mouse model of atopic dermatitis (Surjit et al., 2011). 
 
The GR binding sites (GBSs) are widely distributed in the genome, 
many of them being far from proximal promoters (Weikum et al., 2017). 
Also, specific GBSs vary between tissues, where binding of additional 
cell-type specific TFs at adjacent or overlapping DNA regulatory 
elements modulates an effective GC-dependent transcriptional 
response.  
 
As described above, GR can also interact with other DNA-bound 
TFs to activate or repress gene expression and it does not require the 
binding of GR to DNA sequences, a mechanism known as tethering 
(Weikum et al., 2017). These DNA-bound TFs and their upstream 
signaling pathways are involved in inflammation and include NF-B, 
AP-1, MAPK, among others. 
 
NF-B is a pro-inflammatory TF involved in many biological 
processes, such as cell growth, proliferation, development, and 
inflammatory and immune responses. It is constituted by five subunits: 
p50, p52, p65 (RelA), RelB, c-Rel. Inactive NF-B remains in the 
cytosol bound to its inhibitor , which avoids the NF-B nuclear 
translocation. In response to external stimuli,  is phosphorylated and 
degraded through ubiquitination–proteasome pathway, releasing NF-
B and, thus, promoting translocation to the nucleus where it binds to 
DNA and regulates gene expression (DiDonato et al., 2012). 
 
GR is known to inhibit NF-B activation through different 
mechanisms, including the inhibition of kinases responsible for the 
phosphorylation of IB, its interaction with p65 subunit leading to its 
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cytoplasmic sequestration and IBα up-regulation, in a cell-type 
dependent manner (De Bosscher and Haegeman, 2009).  
 
MAPK family members regulate cellular processes including 
proliferation, differentiation, and inflammation. In mammals, MAPKs 
include extracellular signal-regulated kinases (ERK), JNK, and p38. 
They are activated by phosphorylation and subsequent phosphorylation 
of their downstream targets.  
 
In keratinocytes, MAPKs regulate proliferation and differentiation. 
Several studies have shown GR to negatively regulate MAPKs function 
in keratinocytes (Herrlich, 2001). 
 
AP-1 is a TF involved in various cellular events including 
proliferation, differentiation, survival and apoptosis, which 
demonstrates a relevant role in skin as AP-1 is involved in epithelial 
development, cancer and skin inflammation (Angel et al., 2001). AP-1 
is constituted by two main components including JUN and FOS 
subunits. JUN and FOS can dimerize and JUN is phosphorylated by 
JNK. 
 
AP-1 and GR are described as mutual antagonists (DiDonato et 
al., 2012). However, AP-1 has been also shown as a regulator of the 
accessibility of GR to the chromatin (Biddie et al., 2011). GR can also 
inhibit AP-1 through a non-genomic mechanism resulting in the 
inhibition of JNK.  
 
Non-genomic actions occur rapidly (within minutes) and 
independently of gene expression. GR can regulate signaling 
pathways, including phosphatidylinositol 3-kinase (PI3K) pathway or 
interacting with G protein-coupled receptors and membranous GR. 
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4.3. GR target genes in skin: Anti-inflammatory genes 
regulated by GCs 
Zinc Finger Protein 36/Tristetraprolin (Zfp36/Ttp) and GC-
induced leucine zipper (Gilz/Tsc22d3) are two genes typically 
induced by GR homodimers upon GC treatment in many cell types 
(Brahma et al., 2012; Smoak and Cidlowski, 2006; Ayroldi and Riccardi, 
2009), including keratinocytes (Stojadinovic et al., 2007). 
4.3.1. Zinc Finger Protein 36/Tristetraprolin (ZFP36/TTP) 
Most mammals express three family members, with rodents 
expressing a fourth member. The official gene names are Zfp36, 
encoding tristetraprolin (TTP, also known as ZFP36); Zfp36l1, encoding 
ZFP36L1 (also known as TIS11b); Zfp36l2, encoding ZFP36L2 (also 
known as TIS11D); and Zfp36l3, encoding ZFP36L3 (Brooks and 
Blackshear, 2013). All of these isoforms are found also in humans, 
except Zfp36l3, which is specific for rodents (Fu and Blackshear, 2017). 
 
 
Figure 9. Schematic structure of human ZFP36 protein isoforms. From Fu 
and Blackshear, 2017. 
ZFP36 is a member of a small family of CCCH tandem zinc finger 
proteins involved in the regulation of gene expression by binding to 
adenosine and uridine (AU)-rich elements (ARE) (heptameric sequence 
UAUUUAU), located in the 3′ untranslated region (3′UTR). Once they 
bind they accelerate rates of degradation of target mRNA by recruiting 
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the components of the mRNA degradation machinery (Brooks and 
Blackshear, 2013).  
Studies of gain and loss of ZFP36 have been useful to reach a 
better understanding of the functions of ZFP36. In the case of ZFP36 
KO mouse, the deficiency of this protein leads to a severe syndrome of 
growth retardation, cachexia, arthritis, inflammation and autoimmunity, 
demonstrating the anti-inflammatory role of this endogenous protein. 
However, the treatment with TNF-α antibodies avoid the characteristics 
of the aforementioned syndrome (Fu and Blackshear, 2017), 
demonstrating that TNF-α is a target mRNA of ZFP36. In contrast, the 
increment of the endogenous expression of ZFP36 in mice by 
enhancing its stability leads to the protection against immune and 
inflammatory diseases, including rheumatoid arthritis, psoriasis and 
multiple sclerosis (Patial et al., 2016). 
IL-22 and IL-23 are increased in ZFP36-deficient mice (Härdle et 
al., 2015; Molle et al., 2013), thus linking ZFP36 with autoimmune 
diseases such as psoriasis, as these cytokines were up-regulated in 
this disease (Wolk et al., 2006; Johnson-Huang et al., 2012). ZFP36 
also regulates other inflammatory pathways as ZFP36 physically 
interacts with the p65 subunit of NF-B leading to decreased nuclear 
translocation (Fu and Blackshear, 2017). However, ZFP36 also 
regulates the expression of anti-inflammatory cytokines, such as IL-10 
(Fu and Blackshear, 2017). In fact, ZFP36 has been shown to 
autoregulate its expression by direct binding to its own ARE, thus 
promoting its own degradation (Fu and Blackshear, 2017). 
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4.3.2. Glucocorticoid-induced Leucine Zipper (GILZ)  
GILZ, encoded by Gilz/Tsc22d3 (Transforming growth factor-β-
stimulated clone-22/Glucocorticoid-induced leucine zipper) located on 
the X chromosome (Pinheiro et al., 2013), is a member of the 
transforming growth factor β-stimulated clone 22 domain (TSC22D) 
family of TFs. GILZ was first identified by D’Adamio and Riccardi in 
1997, as a protein highly induced by the synthetic GC dexamethasone 
(Dex) in mouse thymocytes and protected T lymphocytes from 
apoptosis (D’Adamio et al., 1997). Later GILZ was reported to be also 
induced in other cell types, including epithelial cells, lung, liver, brain 
and kidney (De Bosscher and Haegeman, 2009; Shi et al., 2007).  
 
GILZ expression can be transcriptionally induced by 
glucocorticoids, TGF-β and the anti-inflammatory cytokine IL-10 
(Ayroldi and Riccardi, 2009), to name a few. On the other hand, GILZ 
expression can be repressed by inflammatory cytokines (Ayroldi and 
Riccardi, 2009) and by lipopolysaccharide (LPS) through activation of 
TLR4 (Hoppstädter et al., 2012).  
4.3.2.1. Molecular structure and function of GILZ 
GILZ family members contain three distinct domains: an N-
terminus TSC (tuberous sclerosis complex) box, a middle leucine zipper 
domain, and a C-terminus polyproline-rich domain (Beaulieu and 
Morand, 2011; Figure 10).  
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Figure 10. GILZ protein structure showing binding domains of TFs. AP-1, 
activator protein 1; GILZ, glucocorticoid-induced leucine zipper protein; LZ, 
leucine zipper; NF-B, nuclear factor B; PRR, proline-rich region; TSC box 
where ras binds . From Beaulieu and Morand, 2011. 
Human GILZ mRNA presents a high similarity (89%) in nucleotide 
sequence with mouse GILZ and 97% in the coding region (Cannarile et 
al., 2001). 
 
GILZ has been implicated in many processes, including 
immunosuppression, apoptosis (D’Adamio et al., 1997), cell 
proliferation, control of tumorigenesis (Ayroldi and Riccardi, 2009), 
renal sodium transport (Rashmi et al., 2017), adipogenesis (Shi et al., 
2007) and modulation of homeostasis of T cells (Ronchetti et al., 2015). 
The regulation by GILZ of certain cellular functions has been found to 
be cell-type specific and also specific of agent stimulus.  
 
In some cell types, GILZ has been shown to mediate most of the 
effects of GCs, including the inhibition of AP-1 and NF-B 
transcriptional activity (Srinivasan and Janardhanam, 2011), as well as 
inhibition of Ras-driven cell proliferation (Ayroldi and Riccardi, 2009) 
through interaction with these TFs. This has led to the proposal that in 
many organs GILZ acts as an anti-inflammatory mediator of the GCs 
without producing GC-associated side effects (Ronchetti et al., 2015). 
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Figure 11. GILZ interaction with signaling pathways. GCs induce GILZ 
expression, which can inhibit the activity of TFs NF-B and AP-1 and also the 
MAPK pathway through interaction with the upstream RAS and RAF.  
Four isoforms have been characterized as splice variants of the 
Tsc22d3 gene, known as GILZ1, GILZ2, GILZ3 and GILZ4 
(Hoppstädter et al., 2012). GILZ isoforms have also separated functions 
and can be expressed in different organs. For example, GILZ1, the 
canonical isoform with 137 aa, is normally present in thymus, spleen, 
and lung, whereas GILZ2 is detected in testis, liver, skin, and brain 
(Suarez et al., 2012). Among all the GILZ isoforms, GILZ1 is the most 
studied. GILZ1 expression has been reported to be induced by 
aldosterone in the kidney. In addition, GILZ1 inhibits RAF-1 signaling 
pathway through protein-protein interaction leading to ENaC (Epithelial 
Na(+) channel ) activation and also with other components of ENaC 
regulatory complex, in particular, serum and glucocorticoid-regulated 
kinase 1 (SGK1). Physical interaction of GILZ1 with RAF-1 results in 
inhibition of ERK1 and 2 and subsequently, along with SGK1, in the 
synergistic stimulation of ENaC expression through different 
mechanisms.  
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GILZ has been studied in animal models of inflammation and in 
many instances has been shown as an important mediator of 
inflammatory responses in both innate and adaptive immune systems 
(Cheng et al., 2014). 
 
Although GILZ KO male mice are sterile due to impaired 
spermatogenesis (Suarez et al., 2012; Ngo et al., 2013b), GILZ KO 
mice are viable and have been reported to have electrolyte alterations 
and display features resembling familial hyperkalemic hypertension 
(Rashmi et al., 2017). The lack of GILZ did not alter the immune 
response in several diseases and neither decreased the anti-
inflammatory effects of GCs in arthritis (Ngo et al., 2013a). Additionally, 
GILZ-deficient macrophages did not alter their response to LPS (Suarez 
et al., 2012). However, the overexpression of GILZ has been reported 
to be protective in inflammation. For example, transgenic mice 
overexpressing GILZ in T lymphocytes are less susceptible to a spinal 
cord injury mouse model (Esposito et al., 2012). Furthermore, the use 
of GILZ peptide has demonstrated to suppress the inflammation in a rat 
model of experimental autoimmune encephalomyelitis (Srinivasan and 
Janardhanam, 2011). In addition, the injection of GILZ-adeno-
associated virus into the joints in a mouse model of rheumatoid arthritis 
(Ngo et al., 2013a) inhibited the development of the disease similar to 
GC treatment. Consistently, downregulation of GILZ by systemic 
administration of GILZ siRNA had the contrary effect (Beaulieu and 
Morand, 2011). Furthermore, the increased expression of GILZ has 
been shown to be the cause of the resistance to endotoxemia induced 
by LPS of a wild-derived inbred SPRET/Ei mouse strain (Pinheiro et al., 
2013).  
 
As it has been previously described, the phenotypes described for 
GILZ KO or GILZ overexpression in inflammatory models are not 
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always specular images, which likely reflects different roles for the 
endogenous GILZ (KO) versus the therapeutic GILZ (overexpression or 
GILZ peptide injection) (Ngo et al., 2013a). 
4.4. GR epidermal knockout (GREKO) mouse model 
Previous studies in our laboratory using transgenic mice with gain 
and loss of GR function have shown the strong impact of this TF in skin 
homeostasis, demonstrating that GR is a potent anti-inflammatory, anti-
proliferative, and anti-tumor mediator in this tissue (Pérez, 2011). On 
one hand, GR specific overexpression in epidermal keratinocytes, as 
well as generalized loss of GR resulted in major defects in mouse skin 
development (Pérez et al., 2001; Bayo et al., 2008). On the other hand, 
epidermal keratinocyte ablation of GR (GR epidermal KO or GREKO 
mouse) led to skin barrier defects and cutaneous inflammation at the 
perinatal age (Sevilla et al., 2013). Adult GREKO skin was more 
susceptible to perturbation of skin homeostasis with detergent or 
phorbol ester and also to skin carcinogenesis (Sevilla et al., 2013; 
Latorre et al., 2013).  
4.5. Interaction of GR with other transcription factors 
(TFs) 
4.5.1.  Krüppel-like factor (KLF) family  
Krüppel-like factor (KLF) subfamily is formed by 17 mammalian 
zinc finger-containing TFs (evolutionarily conserved) homologs of 
Drosophila Krüppel gene (Pearson et al., 2008). KLF proteins have 
been studied because of their involvement in cardiovascular, bone and 
skin development, as well as in erythrogenesis, neurogenesis and 
adipogenesis, and maintenance of pluripotency and cell proliferation 
(Pearson et al., 2008). KLFs are also relevant in homeostasis of several 
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organs and are involved in several aspects of tumorigenesis (Rowland 
and Peeper, 2006). The functional domains of the KLFs involved in 
gene activation are at the N-terminus and vary between family 
members. For this reason, some KLF members activate and others 
repress gene expression, whereas some can do both functions. KLF4 
is one of the KLF family members that can act either as an activator or 
repressor on gene expression.  
4.5.1.1. KLF4 
KLF4, Krüppel-like factor 4, formerly known as gut-enriched 
Krüppel-like factor or epithelial zinc finger, is a TF with three carboxyl 
C2H2 (Cys2-His2) zinc-fingers, which binds the DNA sequence 5-
CACCC-3 (Pearson et al., 2008) regulating gene expression and thus, 
coordinating a variety of processes, such as proliferation and 
differentiation (Ghaleb and Yang, 2007).  
KLF4 is a nuclear protein, which plays an important role for the 
development of the epithelia, such as cornea, lung and epidermal 
barrier formation (Segre et al., 1999). In fact, KLF4 was first found to be 
highly expressed in the epithelia of intestine (postmitotic cells ) and skin 
(suprabasal layer of the epidermis) (Ghaleb and Yang, 2017; Segre et 
al., 1999) being important for the commitment to terminal differentiation 
of the epidermal keratinocytes and goblet cells in colon (Segre et al., 
1999; Katz et al., 2002). The expression of KLF4 has also been found 
in other non-epithelial tissues, including the lung and cardiac myocytes 
(Ghaleb and Yang, 2017). KLF4 can act as an inductor or repressor of 
gene expression, depending on the cellular context and its association 
with co-activators (p300 and CREB-binding protein) or co-repressors 
(HDAC3) (Ghaleb and Yang, 2017).  
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Furthermore, the overexpression of KLF4, in cooperation with 
other TFs such as OCT3/4, SOX2, and c-MYC induce reprogramming 
of somatic cells by generating the cells termed as induced pluripotent 
stem cells (Takahashi et al., 2007).  
4.5.1.2. KLF4 in epithelial organs 
 
The importance of KLF4 in skin has been determined in 
experiments of gain and loss of function. Klf4 null mice die shortly 
(within 15 h) after birth because of dehydration due to defects in skin 
differentiation, (Segre et al., 1999), as well as a reduced number of 
secretory goblet cells in the colon (Katz et al., 2002). In contrast, the 
overexpression of KLF4 accelerates the skin barrier formation (Jaubert 
et al., 2003). In addition, the antenatal injection of corticosteroids 
synergizes with the ectopic expression of KLF4 in accelerating the 
formation of the epidermal barrier, likely due to overlapping functions of 
KLF4 and GR (Patel et al. 2006). During epidermal differentiation, KLF4 
is regulated by factors, such as ZNF750 and p63, among others 
(Ghaleb and Yang, 2017). Additionally, KLF4 overexpression results 
in inflammation in esophageal keratinocytes in a short period of time, 
whereas longer periods can produce carcinogenesis in mice (Ghaleb 
and Yang, 2017). Unexpectedly, deficiency of KLF4 has been also 
shown to promote an increase of cell proliferation and skin 
carcinogenesis in mice (Ghaleb and Yang, 2017). 
4.5.2. Trp63/p63 
Trp63 encodes p63, a relevant TF belonging to the p53/ p63/p73 
family. It regulates a large number of cellular processes, such as the 
stem cell renewal, balance between proliferation and differentiation, as 
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well as morphogenesis during development, especially in the skin 
(Yang et al., 1999). In fact, p63 is considered one of the master 
regulators of epithelial development (Romano et al., 2012). p63-null 
mice die after birth and show strong defects in the epithelia, limb, 
orofacial region, and external genitalia (Yang et al., 1999). This is 
coincident with the alterations in ectodermal dysplasia found in humans 
caused by p63 mutations (Rizzo et al., 2016). Altered expression of p63 
can be found in several diseases, for example, many squamous tumors 
including those of the head and neck, lung and skin show 
overexpression of p63. Also, p63 expression is altered in psoriasis 
(Rizzo et al., 2016).  
p63 has several isoforms derived from distinct transcripts known 
as TAp63 and N-terminal deleted ΔNp63 arising from two different 
transcription initiation sites (Romano et al., 2012). Additionally, 
alternative splicing can result in α, β, and γ isoforms, which differ in the 
C-terminus. All p63 isoforms bind to the same DNA sequences. 
However, ΔNp63, especially ΔNp63α is the predominant isoform 
present in most epithelial cells including skin keratinocytes and 
regulates the change from simple to stratified epithelium during 
development (Rizzo et al., 2016; Romano et al., 2012). p63 controls not 
only proliferation of keratinocytes, but also keratinocyte differentiation 
via its effect on the ZNF750-KLF4 regulatory axis (Sen et al., 2012). 
Mice overexpressing ΔNp63 in their epidermis display characteristic 
features of atopic dermatitis, such as pruritus, epidermal hyperplasia, 
Th2 cells, elevated levels of cytokines, etc (Rizzo et al., 2016). This is 
consistent with the high expression of ΔNp63 found in human atopic 
dermatitis lesional skin (Rizzo et al., 2016).  
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Significance of the study 
Since GR mediates the therapeutic GC effects for the treatment of 
autoimmune and skin inflammatory diseases, it is important to 
understand the underlying transcriptional mechanisms. This includes 
analyzing how other TFs contribute to GR-mediated gene regulation in 
a given cell type. Also, the fact that chronic treatments with GCs are 
accompanied by side effects has pushed researchers to find other 
molecules with an improved therapeutic index (increased 
benefits/reduced risk). 
The objectives of our work have been divided into two: 
Part I: 
Analysis of the functional cooperation of the 
glucocorticoid (GC) receptor (GR) and Krüppel-like 
factor (KLF) 4 in the regulation of gene expression in 
epidermal keratinocytes.  
To identify GR direct transcriptional targets in epidermal 
keratinocytes, we recently performed GR chromatin 
immunoprecipitation followed by global analysis of the whole genome 
(ChIP-seq). Our results showed that most of the GR binding sites 
(GBSs) corresponded to GREs, but interestingly we also detected 
overrepresentation of binding sites for the TF Krüppel-like factor or KLF. 
Given the relevance of GR and the family member KLF4 in skin 
homeostasis (Pérez, 2011; Ghaleb and Yang, 2017), we focused our 
attention on the possible functional interactions among GR and KLF4. 
Since KLF4 overexpression and GC treatment have been shown to 
regulate a similar set of genes in the skin (Patel et al., 2006), we 
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assessed whether both TFs may regulate coordinately the transcription 
of GC-target genes in keratinocytes.  
 
Using an immortalized adult mouse keratinocyte cell line (Latorre 
et al., 2013), we focused our attention on two GC-regulated genes that 
are involved in inflammation in other cell types, Glucocorticoid-induced 
leucine zipper (Gilz/Tsc22d3) and Tristetraprolin (Zfp36/Ttp). We also 
explored the functional relevance of GR and KLF4 in gene expression 
of these GC-targets using calcium-induced differentiated keratinocytes.  
Part II: 
Functional analysis of GILZ in transgenic mice with 
generalized overexpression: implications in psoriasis. 
Psoriasis is a chronic autoimmune and inflammatory skin disease, 
for which there is no cure and seriously reduce the quality of life of 
patients. Often, GCs are commonly used to repress the hyperactivated 
immune state in the psoriatic skin. 
Gilz/Tsc22d3 is a classical GR transcriptional target gene induced 
by GCs that has been shown to act as an anti-inflammatory mediator in 
different tissues producing therapeutic effects similar to the GCs without 
exerting their side effects (Ayroldi and Riccardi, 2009). Therefore, GILZ 
has been considered as a potential therapeutic tool for certain 
inflammatory diseases (Ronchetti et al., 2015), although very little is 
known regarding its possible role in skin pathophysiology. 
Using transgenic mice model with generalized overexpression of 
GILZ (GILZ-Tg) generated by the group of Prof. Claude Libert, we have 
investigated the role of GILZ in the imiquimod (IMQ) mouse model of 
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psoriasis. This model consists in topical repetitive application of IMQ, 
an agonist of the TLR7, which induces histopathological features and 
molecular alterations including up-regulation of the IL23/IL17 signaling 
pathways, which closely resembles human psoriasis. We have 
assessed the systemic and skin histopathological changes as well as 
the alterations in cytokines and signaling pathways typically up-
regulated in psoriasis in GILZ-Tg relative to control mice. Additionally, 
we used cultured mouse keratinocytes to study the possible effects of 
GILZ overexpression in this cell type. 
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1.1. Isolation and culture of Mouse primary 
keratinocytes (MPKs) 
 
Newborn mice (P0-P3) were sacrificed and tail sample collected 
for genotype analysis. Mice were immersed first in betadine, then in 
sterile distilled water, followed 70% ethanol and finally in PBS. Skin was 
incubated in 0.25% trypsin at 4C overnight, then, the epidermis was 
separated from the dermis, minced, and homogenized in complete 
Eagle’s medium essential medium (EMEM) with 0.05 mM CaCl2 (low 
calcium). The homogenate was filtered, and the solution containing 
MPKs was collected by centrifugation (1200 rpm at 4C for 5 min).  
106 cells were plated into collagen I-coated on 35-mm diameter tissue 
culture dish (BD Biosciences) and cultured at 37C in EMEM. After 24 
h, the medium was replaced with growth medium (complete EMEM 
supplemented with 4% FCS (Biowest) previously treated with Chelex 
100, 100 U/ml penicillin/100 μg/ml streptomycin (Biowest), 2.5 μg/ml 
amphotericin B (Biowest), 10 ng/ml EGF (Peprotech) and 0.05 mM 
CaCl2), and cells were grown until subconfluency using standard tissue 
culture conditions (5% CO2 enriched atmosphere at 37C).  
 
1.2. Culture of immortalized adult mouse keratinocytes 
 
The GR epidermal KO (GREKO) and control keratinocyte cell lines 
were generated from 8-week-old female mouse dorsal skin as 
previously described (Latorre et al., 2013) and cultured on mitomycin C 
treated 3T3-J2 feeders in collagen I-coated flasks in DMEM-Ham’s F12 
(3:1) medium (Gibco) supplemented with 1.8 × 10−4 mol/L adenine, 0.35 
mM calcium, 7.5% Fetal Bovine Serum, 100 U/ml penicillin/100 μg/ml 
streptomycin (Biowest), 2 mM glutamine (Biowest), 0.25 μg/ml 
amphotericin B (Biowest), 5 μg/ml insulin, 10−10 M cholera toxin and       
10 ng/ml EGF (Peprotech). Cells were maintained at standard tissue 
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culture conditions (5% CO2 enriched atmosphere at 32C) and media 
was changed every 48 h. Once keratinocytes reached subconfluency 
they were split as described below: First, culture medium was removed 
and keratinocytes adhered to the plate were washed with 0.02% EDTA 
to remove fibroblasts (feeders). Next, keratinocytes were collected after 
incubation with 0.25% trypsin for 5 min at 37C. After trypsinization cells 
were centrifuged to remove the trypsin and resuspended in medium (as 
mentioned above). Keratinocytes were counted using a hemocytometer 
and cultured on mitomycin C treated confluent 3T3-J2 feeders.  
 
For maintenance of 3T3-J2 feeders cells were grown in DMEM 
medium supplemented with 100 U/ml penicillin/100 μg/ml streptomycin, 
0.25 μg/mL amphotericin B and 10% bovine serum in collagen I-coated 
75 cm2 flasks. Once feeders reached confluency cells were detached 
using 0.02% EDTA and subcultured by splitting them in 1:4 ratio. 
 
1.3. Cell treatments 
 
Prior to treatment with Dex (100 nM), cells were grown for 18–24 
h in respective medium containing charcoal-stripped serum to deplete 
steroid hormones. 
 
To induce terminal differentiation, keratinocytes were incubated 
with medium containing 1.2 mM CaCl2. When indicated, cells were 
pretreated for 6 h with the GR antagonist RU486 (1 μM) or vehicle prior 
to addition of 1.2 mM CaCl2. 
 
 1.4. Immunofluorescence staining  
Cells were grown on collagen I-coated coverslips. After Dex 
treatment (100 nM, 2 h), cells were fixed with 4% paraformaldehyde 
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(PFA) for 10 min, then permeabilized with 0.2% Triton X-100 and 
washed three times with PBS. After blocking in PBS containing 5% 
donkey serum and 0.5% bovine serum albumin for 1 h at room 
temperature, cells were incubated with specific antibodies overnight at 
4 °C. The following day, primary antibody was removed and cells were 
washed three times with PBS. Next, cells were incubated with the 
secondary antibody (Alexa fluor 555 Rabbit, dilution 1/1000; Life 
Technologies) and DAPI (4’-6-Diamidino-2-phenylindole) (Life 
Technologies) at room temperature for 1 h in darkness. After washes, 
samples were mounted using Mowiol (Calbiochem) and analyzed using 
a Leica DM 1000 microscope. Images were processed using Adobe 
Photoshop CS5 software. 
 
1.5. Chromatin immunoprecipitation (ChIP) assays 
 
ChIP experiments were performed as previously described (Sevilla 
et al., 2010), using MPKs or adult keratinocyte cell lines grown to 
confluency in 100 mm culture dishes (Thermo Scientific). Keratinocytes 
were incubated with freshly prepared 1% formaldehyde 8 min at room 
temperature to cross-link the protein-DNA. Next, 1 M Glycine was 
added for 5 min at room temperature to quench unreacted 
formaldehyde. After fixation, cells were washed with cold PBS and were 
collected in a solution containing PBS and protease inhibitors. After 
centrifugation (2000 rpm for 5 min at 4C), supernatant was discarded 
and 200 µl of SDS Lysis Buffer containing protease inhibitors were 
added to the pellet and incubated on ice for 10 min. Cells were 
sonicated using the Bioruptor (Diagenode) to fragment chromatin (<500 
bp fragments) set to high intensity for 30 min with 30 sec on/off cycles. 
Then samples were centrifuged at 13000 rpm at 6C for 10 min to 
remove insoluble material and supernatant was collected to a new tube.  
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For the immunoprecipitation of cross-linked Protein/DNA 1.8 ml of 
dilution buffer containing protease inhibitors and 15 µl of Dynabeads 
Protein A (Life Technologies) was added and incubated for 2 h at 4C 
with rotation to remove proteins or DNA that may bind non-specifically 
to the beads or protein A. Supernatant was recovered by using a 
magnet (DynaMag™-2, Invitrogen) to remove the magnetic beads and 
40 µl of the supernatant was kept appart as Input. Sonicated chromatin 
was immunoprecipitated by adding 3 μg of either rabbit IgG (Sigma) (for 
negative control) or rabbit anti-GR (sc-1004; Santa Cruz Biotechnology) 
or anti-KLF4 to the supernatant fraction and incubated overnight at 4C 
with rotation. The following day 20 µl of magnetic beads were added 
and incubated for 2 h at 4C with rotation to collect the 
antibody/antigen/DNA complex. Using the magnet, supernatant was 
discarded and beads were washed with 1 ml of the following cold 
buffers: Low Salt, High Salt, LiCl and TE. Afterwards, protein/DNA 
complexes were eluted by incubation with 500 µl of elution buffer (1% 
SDS and 0.1 M NaHCO3) at 25C shaking at 300 rpm for 15 min. After 
ChIP, reversion of DNA-protein cross-linking was performed by adding 
20 µl of 5M NaCl and incubating overnight at 65C. Afterwards, samples 
were treated with 1 µl of 30 mg/mL of RNase A (Sigma) (30 min at 37C) 
to remove contaminant RNA. To remove proteins, samples were 
incubated with a solution constituted by 0.5 M EDTA, 1 M Tris-HCl and 
proteinase K (10 mg/ml) at 55C for 2 h.  
 
The DNA was purified by phenol-chloroform extraction: after 
addition of the phenol-chloroform-isoamyl alcohol (500 µl), samples 
were mixed and centrifuged 13000 rpm at 4C for 15 min. Upper 
aqueous phase was transferred to a fresh tube and 500 µl of chloroform 
was added, mixed and centrifuged again. Next, upper aqueous phase 
was transfer to a fresh tube and Glycogen (Roche) was added to 
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visualize pellet, as well as 18.8 μl of 5 M NaCl. Then samples were 
incubated overnight at -20C after addition of 1 ml of absolute ethanol. 
Next day, samples were centrifuged 13000 rpm for 30 min at 4C. 
Supernatant was removed and pellet was washed with 70% ethanol 
and centrifuged again at 13000 rpm for 10 min. Finally, supernatant was 
removed and pellet was air-dried before resuspending in nuclease-free 
water. DNA was quantified in Nanodrop measuring absorbance at 260 
nm. 
 
Table 1. Components of the buffers used for the beads washes in the ChIP 
assay. 
QPCR was performed to assess the relative amplification of specified 
genomic sites in Dex versus mock-treated ChIPs, which were 
normalized to the amplification values of respective inputs. 
 
 
Table 2. Sequences of primers used in the ChIP-QPCR. 
1.6. RNA isolation 
 
Total RNA was isolated either from mouse dorsal skin, immortal 
keratinocyte cell lines or mouse primary keratinocytes, using TRIzol 
(Life Technologies). A small section of mouse dorsal skin was 
Low Salt High Salt LiCl TE
0.1% SDS 0.1% SDS 0.25 M LiCl 1 mM EDTA
1% Triton X-100 1% Triton X-100 1% IGEPAL-CA630 10 mM Tris-HCl pH 8.0
2 mM EDTA 2 mM EDTA 1% deoxycholic acid 
20 mM Tris-HCl pH 8.1 20 mM Tris-HCl pH 8.1 1 mM EDTA
150 mM NaCl 500 mM NaCl 10 mM Tris-HCl pH 8.1
Gene Forward pimer 5'-3' Reverse pimer 5'-3'
Axin 2 AGCTCTAGCTGGAGGCTGAT ACAGGACCTGGCATGGATTG
Hipk2 GGGTTCCTGCAGGGGAATATCTGT ATGTGCCATGCTGGGCTTGAGA
Per1 TACAGGACCGCTGTCGTTGGGT CGTCAAAGCGGAGGCAGGAGG
Ror1 ATGCTCACATTCCGACTGGT AAGCAGGCTTTAGCTTGGGA
Tsc22d3/Gilz2 GGAGGGAATGCAACTGGGAG CCCCTCCCTTGAATGCTGAA
Zbtb16 GCCGCCAGAACAATGCGTACAGA AGCTAGGGAGAGCCAAAGCGGG
Zfp36 TCCTCTATCAAGTCCGCCCA AGGAACGGGATGTTTCCGTC
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immersed in 1 ml TRIzol and homogenized with the aid of a Polytron 
homogenizer to maximum speed for 1 min. Homogenates were 
centrifuged 8700 rpm at 4C for 10 min to remove debris and insoluble 
material. Supernatant was incubated at room temperature for 5 min. 
Next, 200 µl chloroform was added to the supernatant and tubes were 
shaken vigorously for 15 seconds and subsequently kept at room 
temperature for 10 min. After centrifugation (11400 rpm at 4C for 15 
min), colorless upper aqueous phase was collected and transferred to 
a fresh tube. Isopropyl alcohol (500 l) was added and samples were 
agitated and were incubated at room temperature for 10 min. After 
centrifugation (11400 rpm at 4C for 10 min) supernatant was discarded 
and pellet was washed with 1 ml of 75% ethanol and centrifuged (11400 
rpm at 4C for 5 min). Ethanol was discarded and air-dried pellet was 
dissolved in nuclease-free water and incubated at 55C for 10 min. 
Finally, RNA was quantified using NanoDrop measuring the 
absorbance at 260 nm and the absorbance ratio 260/280 to determine 
the RNA purity. Samples were stored at -80C until use.  
After RNA isolation, DNase treatment of the samples was 
performed according to the manufacturer’s instructions (Thermo 
Scientific). 
1.7. Synthesis of cDNA (reverse transcription)  
 
RNA samples (1 µg) were reverse transcribed to make cDNA using 
RevertAid H Minus Reverse Transcriptase and using oligo dT primers. 
  
For each reaction, oligo dT primers (Thermo Scientific) were added 
to 1 µg of RNA. Next, nuclease-free water was added to a final volume 
of 12.5 µl and mixed was incubated at 65C for 5 min. Then, 8 µl of the 
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mix was added, containing 5x buffer, mix of nucleotides (10 mM), 20 
units of RNase inhibitor (Thermo Scientific) and 200 units of reverse 
transcriptase (Revertaid, Thermo Scientific). Next, samples were 
incubated at 42C for 1 h. Subsequently, the enzyme was inactivated 
by heating at 70C for 10 min and was kept at 4C (on ice). Finally, 
cDNA was further diluted 1:10 for quantitative RT-PCR. 
 
1.8. Quantitative RT-PCR  
 
Quantitative real-time PCR was performed using 8 µl of the diluted 
(1:10) cDNA, specific primers (10 µM) and 10 µl of FastStart Universal 
SYBR Green Master ROX (Roche) to a final volume of 20 µl and 
analyzed on Applied Biosystems 7500 Fast real time PCR machine. 
The following QPCR conditions were used: samples were incubated for 
20 seconds at 50C followed by a second incubation for 10 min at 95C 
to activate the polymerase. Afterwards, they were amplified for 40 
cycles, consisting of denaturation for 15 seconds at 95C followed by 
annealing and extension at 60C for 1 min. 
 
Hprt1, Ubc and Rpl were used as housekeeping genes. At least 
four to five biological replicates were used per genotype and treatment. 
Technical triplicates were assessed to calculate the mean value ± SD. 
The sequences of primers used are represented in the table below:  
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Table 3. Sequences of primers used in the RT-QPCR. 
 
1.9. Klf4 knockdown  
 
Keratinocytes were plated in collagen I-coated 35 mm dish. Then 
they were transfected with 25 nM Klf4 specific (L04001010005) or 
Control (D0018101005) On-Target plus siRNA Smartpool (Thermo 
Scientific) using Lipofectamine 2000 (Life Technologies) and Optimem 
medium (Life Technologies). Transfection was performed in DMEM-
Ham’s 12 medium without antibiotics or antimycotic. Medium was 
changed 5 h after addition of siRNA–Lipofectamine 2000 complexes. 
Experiments were conducted 48 h following transfection. 
 
 
 
 
 
Gene Forward pimer 5'-3' Reverse pimer 5'-3'
Axin 2 AGCGCCAACGACAGCGAGTT CTTGGGCAGGCGGTGGGTTC
Hipk2 ACACACCTGCTTGACTTCCCCCA TGGATGCCGCTGAGGGCTGGTT
Klf4 GTGCCCCGACTAACCGTTG  GTCGTTGAACTCCTCGGTCT  
Nr3c1 AAAGAGCTAGGAAAAGCCATTGTC TCAGCTAACATCTCTGGGAATTCA
Per1 GGGAGACAAGAAGCCCCCGGA GTGTCGGCGACCAGGGGGAA
Ror1 CCGCAACCCTGGCAACCAGA AGCCAGGGGAATGGCCACACT
Sprr2d TGGTACTCAAGGCCGAGA TTTGTCCTGATGACTGCTGAAGAC
Tsc22d3/Gilz2 CTGTTGGCCTCGACTGCTG GCCGAAAGTTGCTCACGAAG
Zbtb16 CCCAGTTCTCAAAGGAGGATG  TTCCCACACAGCAGACAGAAG
Zfp36 CCACCTCCTCTCGATACAAGA GCTTGGCGAAGTTCACCCA
Hprt1 AGTGTTGGATACAGGCCAGAC CGTGATTCAAATCCCTGAAGT
Ubc AGGTCAAACAGGAAGACAGACGTA TCACACCCAAGAACAAGCACA
Rpl CCTGCTGCTCTCAAGGTT TGGTTGTCACTGCCTCGTACTT
S100a8 AAATCACCATGCCCTCTACAAG CCCACTTTTATCACCATCGCAA
S100a9 ATACTCTAGGAAGGAAGGACACC TCCATGATGTCATTTATGAGGGC
Il-17f CCCAGGGCTGTTCTAATTCCTT GACACAGGTGCAGCCACCTTT
Stat3 AGCTGGACACACGCTACCT AGGAATCGGCTATATTGCTGGT
Il-22 TCAGTGCTAAGGATCAGTGCT TGATTGCTGAGTTTGGTCAGG
Il-23a AAAATAATGTGCCCCGTATCCAG GCTCCCCTTTGAAGATGTCAG
Il-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC
Tsc22d3/Gilz1 CGGTCTATCAGCTGCACAATTT ACATCCCCTCCAAGCAGAGA
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1.10.  Western blotting 
1.10.1. Protein isolation 
 
Whole-cell protein extracts from mouse dorsal skin and cultured 
keratinocytes were isolated and prepared for posterior analysis. 
Collected frozen sample (skin, spleen, gut) were ground in liquid 
nitrogen using a mortar and a pestle. Next, protein was extracted from 
tissue (Buffer C: 20 mM HEPES pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 
mM EGTA and 25% glycerol) or cells (RIPA buffer: 50 mM Tris–HCl pH 
8, 150 mM NaCl,1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) 
using protease (complete Mini EDTA-free; Roche) and phosphatase 
inhibitors (PhosStop; Roche) by three freezing (liquid nitrogen) and 
thawing (37C) cycles. Afterwards, 10% Igepal CA-630 was added to 
the lysed samples and they were incubated on ice for 15 min. 
Subsequently, samples were centrifuged 10000 rpm at 4C for 20 min. 
Protein concentration of collected supernatants was measured by 
Bradford reaction (Bio-Rad) using Wallac Victor 1420 multilabel 
counter. Bovine serum albumin was used for the preparation of the 
standard curve. 25-30 µg of protein were used for the western blots. 
re.co 
       1.10.2. Gel electrophoresis and protein transfer  
 
Protein samples (25-30 µg protein) were boiled in Laemmli buffer 
(containing 6% SDS and 1% β-Mercaptoethanol) at 95C for 10 min for 
protein denaturation. Denaturated protein extracts and molecular-
weight size marker (Spectra™ Multicolor Broad Range Protein Ladder; 
Thermo Scientific) to identify the approximate size of the proteins were 
loaded onto 8-15% SDS-polyacrylamide (SDS-PAGE) gel constituted 
by the following components: 
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Table 4. Components of the polyacrylamide gels.  
 
Samples were run at 100 V for 2 h and transferred to a 
nitrocellulose membrane (Hybond ECL, Amersham) at 80 mA for 75 
min using transfer buffer (25 mM Tris, 192 mM glycine and 20% 
methanol) and semi-dry blotting system (Trans Blot SD Semi-dry 
Transfer Cell, Bio-Rad). Gel loading control was done by Ponceau S 
staining on the membranes after transfer.  
 
1.10.3. Blocking, incubation and band detection  
 
Blocking buffer (5% non-fat dry milk in 0.1% Tween 20 (Sigma) in 
PBS buffer) was used to block the membrane for 1 h at room 
temperature and then incubated overnight at 4C in primary antibody 
diluted in the blocking buffer followed by the three washes with PBS-
0.1% Tween 20 buffer. Next, peroxidase-conjugated secondary 
antibodies were diluted in the same blocking buffer solution and 
incubated for 1 h at room temperature. After the incubation, membranes 
were washed three times with PBS-0.1% Tween 20 buffer. The 
immunoreactive bands were detected using ECL2 (Thermo Scientific) 
with the ImageQuant 4000 Biomolecular Imager (GE Healthcare). 
Quantification of the protein band density was determined using Image 
J software. Experiments were performed with a minimum of three 
biological replicates. Tubulin or actin was used as protein loading 
control. Peroxidase-conjugated secondary antibodies were purchased 
from GE HealthCare.  
8% 10%
40% polyacrylamide 750 µL 40% polyacrylamide 2.4 mL 3 mL
1 M Tris-HCl pH 6.8 750 µL 1.5 M Tris-HCl pH 8.8 3 mL 3 mL
10% amonium persulfate 60 µL 10% amonium persulfate 120 µL 120 µL
10% SDS 60 µL 10% SDS 120 µL 120 µL
TEMED 6 µL TEMED 7.2 µL 4.8 µL
H2O 4.4 mL H2O 6.36 mL 5.76 mL
Stacking gel 5%
Separating gel
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The primary and secondary antibodies are listed below: 
 
Table 5. List of the antibodies used in the western blot analysis. 
2. Immunoprecipitation  
 
Keratinocytes were lysed using a buffer containing 50 mM Tris      
pH 7.6, 150 mM NaCl, 5 mM EDTA, 0.5% Igepal CA-630 with protease 
and phosphatase inhibitors (Roche). Proteins were immunoprecipitated 
using 2 μg of KLF4 specific antibody or rabbit IgG as a negative control 
and Dynabeads Protein A (Life Technologies). After washing with buffer 
containing 0.2% Igepal CA-630, proteins were eluted from beads by 
boiling in Laemmli buffer for analysis by immunoblotting. 
 
HRP-conjugated Clean-blot IP Detection Reagent (Thermo 
Scientific) was used for immunoblotting of immunoprecipitation 
experiments. 
 
3. Mice  
Female mice were maintained at 12 light/12 dark cycles, caged in 
groups (4–6 per cage) under SPF conditions, and having access to ad 
Antibody Dilution Company Species
GR (sc-1004) 1/1000 Santa Cruz Biotechnology Rabbit
Klf4 (sc-20691) 1/1000 Santa Cruz Biotechnology Rabbit
p63 (sc-8431) 1/1000 Santa Cruz Biotechnology Rabbit
p-GR Ser 211 (4161S) 1/1000  Cell Signaling Technology Rabbit
GILZ (14-4033) 1/1000 eBioscience Rat
pSMAD2/3 Ser 465/467 (3108P) 1/1000  Cell Signaling Technology Rabbit
SMAD2 (5339P) 1/1000  Cell Signaling Technology Rabbit
SMAD3 (9523P) 1/1000  Cell Signaling Technology Rabbit
Tubulin (T6199) 1/4000 Sigma-Aldrich Mouse
Actin (A2066) 1/1000 Sigma-Aldrich Rabbit
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libitum food and water. All the animal protocols were approved by the 
ethical committee of the Faculty of Sciences at Ghent University.  
 
3.1. Generation of GILZ transgenic mice  
Mice were generated in the laboratory of Prof. Claude Libert 
(Inflammation Research Center, Ghent) as follows: 
 
Conditional GILZ-Tg overexpressing mice were generated using a 
Gateway-compatible ROSA26 locus targeting vector (Nyabi et al., 
2009), knocking in the construct containing the mouse Tsc22d3/Gilz-1 
cDNA preceded by a loxP flanked stop cassette under control of the 
ROSA26 promoter, and followed by an IRES-EGFP (Enhanced Green 
Fluorescent Protein) cDNA. Chimeric mice that transmitted the 
transgene to their offspring were generated, once the targeted 
embryonic stem cell clones were identified correctly by Southern blot 
analysis. GILZ-Tg mice that were used for experimentation were 
generated by intercrosses of one transgenic line homozygous for the 
GILZ-loxP construct and mice carrying one allele of Nestin-cre, which 
express Cre in all cell types (Betz et al., 1996).  
 
Due to some degree of leakiness of the loxP flanked stop 
cassette, control mice with exactly the same genetic background 
(C57BL/6) as the GILZ-Tg mice, but without the cassette (GILZ-Wt) 
were used. 
 
For genotyping, the following primers and conditions were 
used: PCR cycling for the stop cassette consisted of denaturation at 
94°C for 5 min, 35 cycles of 94°C for 1 min, annealing at 57°C for 1 min 
and extension at 72°C for 2 min, followed by 10 min at 72°C. Primer 
sequences were used as followed: forward primer 5’ 
GTGATCTGCAACTCCAGTCTTTC 3’; reverse primer 5’ 
CCATCTGCACGAGACTAGTG 3’. 
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3.2. Imiquimod-induced psoriasis mouse model  
For the IMQ experiment female GILZ-Wt and GILZ-Tg mice of 8-
12 weeks of age were used. Either Aldara® (containing 5% IMQ, 3 M 
Pharmaceuticals; 62.5 mg) or control cream (Ava, Fagron NV) was 
applied topically on mouse dorsal shaved skin daily for 7 days. Skin 
erythema and scaling were daily scored independently on a scale from 
0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; 4, very marked. Gut, 
spleen and a section of dorsal skin were collected, snap-frozen in liquid 
nitrogen and stored at -80°C until use or fixed in 70% ethanol for two 
days and embedded in paraffin for immunohistochemical analysis. 
Spleens were collected and weight was expressed relative to mouse 
body weight. In total 31 animals were used in two independent 
experiments (15 GILZ-Wt, 16 GILZ-Tg). 
3.3. Tissue collection  
After sacrificing mice, skin samples from adult and newborn (P0) 
mice were dissected and immediately fixed in 70% ethanol for 48 h at 
room temperature. 
 
3.4. Histological procedures  
After fixation, skin samples were mounted in cassettes and 
introduced in the tissue processor (Spin Tissue Processor STP 120, 
Myr) where samples were dehydrated by immersion in a series of 
ethanol solutions of increasing concentration, followed by xylene 
(Merck) and finally in paraffin (Panreac). Subsequently, tissues were 
embedded in paraffin blocks in a Modular Tissue Embedding Center 
350, Myr. Then paraffin-embedded tissue blocks were sectioned 4 µm 
using a microtome (Rotary microtome HM 340 E, Microm) and sections 
were placed on the polylysine-coated microscope slides and air dried 
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(Menzel Glässer). Tissue processor protocol was followed as shown in 
the table below: 
 
Table 6. Steps followed in the tissue processor.  
 
3.5. Hematoxylin-eosin staining 
Mouse dorsal skin sections (n=15 GILZ-Wt and 16 GILZ-Tg) were 
first deparaffinized by heating at 60C for 30 min and posterior 
incubation twice in xylene for 10 min. Next, sample sections were 
hydrated by immersion in a series of ethanol solutions of decreasing 
concentration (100%, 90%, 70% y 50%), followed by water. After 
hydration, sample sections were immersed in hematoxylin Harris 
(Panreac), Bluing Reagent (Thermo Scientific) and yellow eosin 
(Panreac). Afterwards, sample sections were dehydrated by immersion 
in a series of ethanol solutions of increasing concentration (50%, 70%, 
90% and 100%) and xylene. Finally, sample sections were mounted 
with a synthetic resin which is a xylene-based mounting medium 
like DPX (Merck). Samples were observed using the optical microscope 
Leica DM 1000 and images were acquired using the digital camera 
Leica EC3. 
 
 
 
Reactive Time (hours)
70% Ethanol 1
95% Ethanol 3
95% Ethanol II 1.5
100% Ethanol I 2
100% Ethanol II 6
Xylene I 1.5
Xylene II 2.5
Paraffin I 2.5
Paraffin II 2
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 3.6. Immunohistochemical analysis 
 
Mouse dorsal skin sections (n=15 GILZ-Wt and 16 GILZ-Tg) were 
first deparaffinized by heating at 60C for 30 min and posterior 
incubation twice in xylene for 10 min and twice in 100% EtOH for 10 
min. Subsequently, to block the endogenous peroxidase activity, 
sample sections were immersed in a solution of methanol: H2O2 (29:1) 
for 20 min at room temperature in the dark. Next, sections were blocked 
with 5% fetal bovine serum in PBS for 20 min, followed by incubation 
with the primary antibody diluted in a solution of 1% bovine serum 
albumin (in PBS) overnight at 4C. Next, samples were washed with 
PBS to remove the excess of primary antibody, and secondary biotin-
conjugated antibody (diluted in a solution of 1% bovine serum albumin 
(in PBS) (Jackson ImmunoResearch, West Grove, PA) was added and 
incubated at room temperature for 1 h. After washes with PBS, sample 
sections were incubated with the avidin-biotin-peroxidase complex 
(ABC, Vectastain; PK-6100; Vector Laboratories). Then sections were 
visualized using a kit of diaminobenzidine (DAB; Vector Laboratories), 
a chromogen for immunohistochemical staining as it is a peroxidase 
substrate and reaction was stopped by immersion in water. Next, 
sections were counterstained with hematoxylin. Samples were 
dehydrated and mounted as described in the “hematoxylin-eosin 
staining” section. 
 
 
Table 7. Antibodies used in the immunohistochemistry of the mouse skin. 
 
Antibody Dilution Company Species
K6 (PRB-169P) 1/2000 Covance Rabbit
loricrin (PRB-145P) 1/1000 Covance Rabbit
Caspase-14 (sc-5628) 1/1000 Santa Cruz Rabbit
p-SMAD2/3 (sc-11769-R) 1/1000 Santa Cruz Rabbit
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4. Keratinocyte transfection and dual luciferase 
assay 
4.1. Keratinocyte transfection  
 
For transfection experiments, keratinocytes were seeded on a 
collagen I-coated 24-well plate to a confluence of about 80% 24h prior 
transfection. Then, transient transfections were performed with the 
indicated plasmids using Lipofectamine 2000 Reagent (Invitrogen) 
according to the manufacturer’s protocol. Renilla was used as a co-
reporter for normalization of experimental variations such as differences 
in transfection efficiencies. After 5 h, transfection medium was replaced 
by growth medium (low calcium medium) and transfected keratinocytes 
were incubated with 1 ng/µl TGF-β1 for 20 h. The empty expression 
vector cassette pCDNA4 was provided by Invitrogen. 
 
The pEGFP-C1-Gilz plasmid was kindly provided by Prof. Claude 
Libert (Inflammation Research Center, Ghent). 
 
The SMAD-Luc/reporter plasmid containing SMAD Binding 
Regions (Alonso-Merino et al., 2016) was kindly provided by Dr. Ana 
Aranda (Instituto de Investigaciones biomédicas “Alberto Sols”, CSIC-
UAM, Madrid). 
4.2. Dual luciferase reporter assay  
To examine the transcription activity, dual luciferase reporter 
assays were performed using the dual luciferase assay system 
(Promega). After removing the cell supernatant of the transfection 
assay (24-well plate), 100 µl diluted Passive Lysis Buffer (Promega 
Corp., Madison, WI) was added and shaken at 1000 rpm for 15 min at 
25 °C (in a thermomixer comfort from Eppendorf®). Then 25 µL from 
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each cell homogenate was added to a 96-well plate and the luciferase 
activity was measured using a Wallac Victor2 1420 multilabel counter 
according to the manufacturer’s protocol. Firefly-luciferase activity of 
each well was corrected using the corresponding Renilla-luciferase 
activity.  
 
5. Keratinocyte transfection and treatment with 
IL-17A  
 
Keratinocytes were seeded in a 6-well plate to a confluence of 
about 80% 24 h prior to transfection. 5 h after transfection, medium was 
replaced and cells were treated with recombinant human IL-17A (100 
ng/ml for 24 h, R&D Systems). After 24 h, keratinocytes were collected 
and lysed for posterior RNA isolation and determination of S100a8 
expression by RT-QPCR. 
 
6. Determination of serum cytokine levels  
 
This protocol was performed in the laboratory of Prof. Claude 
Libert. IL-17A, IL-17F, and TNF-α were analyzed in the serum samples 
using Luminex technology (BioPlex, Bio-Rad) following the 
manufacturer’s protocol. 
 
7. Isolation of lymph nodes, treatments, and 
determination of IL-17A levels  
 
This protocol was performed in the laboratory of Prof. Claude 
Libert. At day 7 ear-draining (brachial) lymph nodes were isolated from 
GILZ-Tg and GILZ-Wt mice treated with Aldara or control cream. After 
mincing the lymph nodes through a 70 μm cell strainer (BD Falcon) to 
obtain single cell suspensions, cells were cultured in RPMI-1640L 
medium supplemented with Glutamax, 10% fetal calf serum, 
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gentamycin and β-mercaptoethanol (Gibco; Life Technologies). Then 
cells were re-stimulated with 10 μg/ml Aldara or control cream for 3 d. 
The levels of IL-17A cytokine production was measured in the 
supernatant of cultured cells using Luminex technology (BioPlex; Bio-
Rad) in accordance with the manufacturer’s protocol. 
 
8. Statistical Analysis  
Experimental data were analyzed using Microsoft Excel and IBM 
SPSS Statistics 23 software. In all graphs, data are expressed as the 
mean value ± SD. Prior to parametric testing, the Levene’s test was 
used to determine whether samples within groups had equal variance. 
For comparisons between two experimental groups, we used the 
Student’s unpaired two-tailed t-test. For comparisons multiple 
experimental groups, we used the one-way ANOVA which if statistically 
significant was followed by a post hoc Tukey multiple comparison test. 
P values less than 0.05 were considered statistically significant.  
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It is well known that the synthetic GC dexamethasone (Dex) 
induces the translocation of GR to the nucleus in many cell types, where 
it binds to specific sequences in the DNA and regulates the expression 
of genes associated with homeostasis and differentiation 
(Ramamoorthy and Cidlowski, 2016). In mouse primary keratinocytes 
(MPKs), Dex also induced GR translocation to the nucleus, as shown 
by immunofluorescence (Figure 12; and Sevilla et al., 2010). 
 
 
Figure 12. Dex induces GR nuclear translocation in mouse primary 
keratinocytes (MPKs). Representative confocal microscopy image of GR 
translocation to the nucleus induced after Dex (2h, 100 nM) treatment on MPKs.  
  
Previous studies in our laboratory have identified genes directly 
regulated by Dex-activated GR in MPKs by GR ChIP followed by global 
analysis of the whole genome (ChIP-seq). These data have permitted 
us to identify 104 peaks with GR binding in keratinocytes after Dex 
treatment. The identified associated genes included Tsc22d3/Gilz, Per1 
(Period circadian clock 1), Ror1 (receptor tyrosine kinase-like orphan 
receptor) and Zfp36, already described in literature as directly regulated 
by GR in several cell types including keratinocytes (Newton, 2014; 
Stojadinovic et al., 2007). We also identified novel GR-target genes in 
keratinocytes such as Axin2, an inhibitor of Wnt signaling also known 
to be induced by Dex in other tissues (Naito et al., 2015); Hipk2 
(homeodomain-interacting protein kinase 2), which encodes a nuclear 
serine-threonine kinase that regulates gene expression by 
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phosphorylating TFs and can act as an oncogene or tumor suppressor 
(Imberg-Kazdan et al., 2013); and Zbtb16 (zinc finger and BTB domain 
containing 16), which encodes the protein Zbtb16 and also known as 
PLZF (promyelocytic leukemia zinc finger). 
However, the exact DNA binding sites of GR and mechanism of 
regulation of these genes in keratinocytes were not previously 
investigated.  
1. 1. Validation of GR direct transcriptional targets 
identified in mouse keratinocytes by GR ChIP-seq  
 
In order to validate the results obtained from ChIP-seq analysis, 
we performed an independent experiment of GR ChIP using cultured 
MPKs that were either left untreated or treated with Dex for 2 h followed 
by qRT-PCR using specific sequence primers. As shown, Dex 
treatment led to the GR recruitment to the regulatory sequences of the 
selected genes (Figure 13). The extent of GR recruitment was found to 
be 2.5-fold for Axin2 and ~20-25-fold for Ror1, Tsc22d3 and Zfp36. 
 
Figure 13. Validation of GR transcriptional targets in MPKs. Primary 
epidermal keratinocytes from newborn mice were cultured and treated either 
with Dex (100 nM, 2 h) or vehicle followed by GR ChIP and qRT-PCR using 
specific sequence primers for the indicated genes. Mean values ± SD show fold 
GR recruitment in Dex- versus mock-treated MPKs. Asterisks indicate 
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statistically significant differences between groups (Student’s t-test, n = 3; *p < 
0.05, **p < 0.01). 
Subsequently, we evaluated the expression of these genes after 
Dex treatment and found significant up-regulation in all cases (Figure 
14). Dex induced the mRNA levels of Axin2, Hipk2, Ror1 and Zfp36 by 
approximately 2-fold while Tscd22d3 and Per1 expression were 
induced around 6-fold (Figure 14). Remarkably, Dex induced the 
expression of the TF Zbtb16, a general transcriptional repressor, by 
more than 250-fold. Although its expression has been reported to be 
induced in response to GCs in lymphoid cells in acute lymphoblastic 
leukemia protecting cells from apoptosis acting as a repressor on Bim-
transcription (Wasim et al., 2010), there is no mention of the GR 
recruitment to its regulatory sequences. ZBTB16 has been implicated 
in tumor suppression in melanoma (Shiraishi et al., 2007).  
 
 
 
 
Figure 14. Evaluation of gene expression in MPKs in response to Dex. 
Gene expression of the indicated genes was assessed in cultured MPKs after 
Dex treatment (100 nM, 3 h) by RT-QPCR. Mean values ± SD show the relative 
gene expression in Dex- versus mock-treated. Asterisks indicate statistically 
significant differences between groups (Student’s t-test; n = 3; *p < 0.05,             
**p < 0.01).  
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However, no clear correlation between the level of transcriptional 
activity (induced by Dex) and GR recruitment was observed. This fact 
has also been reported by other authors (Schöne et al., 2016). For 
example, the Zbtb16 GBS, which showed one of the highest 
transcriptional activities among the validated genes showed lower 
occupancy (Figures 13 and 14).  
 
1.2. Analysis of TF binding motifs in GR ChIP-Seq 
peak regions 
 
We wondered whether the genomic DNA sequences associated 
with GR ChIP-seq peaks correlated with the overrepresentation of one 
or several TF binding motifs. For this, we used MEME 
(http://meme.nbcr.net/meme/), a web-based tool for analyzing motifs in 
DNA. Our survey showed that most of the 104 regulatory sequences 
contained canonical binding motifs for GR (GREs: 
AGAACAnnnTGTTCT, (64%), AP-1 (TGAGTAAT, 28%) and KLF 
(Krüppel like factor) (CACCC; 43%) (supplementary table 1). This 
overrepresentation of binding sites demonstrates the importance of 
these TFs in the early response to GCs of epidermal keratinocytes. It 
also suggests that GR, in combination with these TFs coordinately 
regulates gene expression in this cell type. 
 
Overrepresentation of GRE binding motifs was expected and the 
GR/AP-1 interference has been also widely described (Newton, 2014). 
It is known that GR inhibits AP-1 through protein-protein interaction 
(tethering) resulting in inhibition of the AP-1 activity (DiDonato et al., 
2012), and thus repression of numerous pro-inflammatory genes, such 
as IL-6, IL-1β y TNF-α (De Bosscher and Haegeman, 2009; Newton, 
2014). Alternatively, GR can bind to composite regulatory elements that 
contain both the GRE and AP-1 motifs (Newton, 2014). Additionally, it 
has been reported that AP-1 colocalizes in the DNA with GR and 
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promote its accessibility to regulatory elements in the DNA (Biddie et 
al., 2011). This mechanism has been also shown for other TFs 
belonging to the NR family, such as estrogen receptor (Miranda et al., 
2013). 
 
However, the examples of functional interactions between GR and 
KLFs have been less studied and depend on the expression patterns of 
various KLF members (Chinenov et al., 2014; Knoedler et al., 2014). As 
mentioned in the introduction section, KLF is a family of TFs that 
mediate many relevant biological processes. All the family members act 
as TFs binding to specific DNA sequences (CACCC or related GC-rich 
elements) in the promoter and enhancer regions. One of the members 
of the family, KLF4, is highly expressed in the differentiated and post-
mitotic cells in gut and skin. Among the different KLF members, we 
focused on KLF4 given the crucial role of this TF in epidermal 
development and homeostasis (Segre et al., 1999; Jaubert et al., 2003). 
 
Both GR and KLF4 play important roles in epidermal development 
and homeostasis, which is demonstrated by either inhibiting or 
overexpressing these TFs individually (Pérez, 2011; Ghaleb and Yang, 
2017). 
 
Absence of KLF4 in mice led to abnormal epidermal barrier 
formation due to alterations in the expression of the late-differentiation 
structures from the cornified envelope (Segre et al., 1999) and 
increased tumorigenesis when chemically induced (Ghaleb and Yang, 
2017). On the other side, ectopic expression of KLF4 in vivo in basal 
keratinocytes accelerated the barrier acquisition in mouse (Jaubert et 
al., 2003). However, inducible activation of KLF4 in the epidermal basal 
layer led to an unexpected epithelial dysplasia (Foster et al., 2005). The 
KLF4 acts as a tumoral suppressor or oncogene depending on the 
cellular context (Rowland and Peeper, 2006).  
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Mice overexpressing GR in epidermis and other stratified epithelia 
showed defects in the cutaneous development as well as in ocular, 
tooth epithelia, and secretory glands, and delay in cutaneous wound 
healing. Also, mice with epithelial GR overexpression showed 
protection against epidermal inflammation and skin tumorigenesis 
(Pérez et al., 2001; Cascallana et al., 2005; Budunova et al., 2003; 
Pérez, 2011; Sanchis et al., 2012).  
 
On the other side, mouse models with total or epidermis-specific 
GR inactivation (GRnull and GR epidermal KO/GREKO mice, 
respectively) displayed impaired epidermal barrier formation (Bayo et 
al., 2008; Sevilla et al., 2013). Also, GREKO adult mice were more 
susceptible to inflammatory stimuli and more prone to development and 
conversion of skin tumors (Sevilla et al., 2013; Latorre et al., 2013). 
 
Furthermore, both antenatal GC treatment and the ectopic 
expression of KLF4 accelerated the formation of the skin barrier (Segre, 
2003; Jaubert et al., 2003) and there was overlapping between target 
genes regulated during the epidermal development by antenatal 
corticosteroids and KLF4 (Patel et al., 2006; Sevilla et al., 2010; Sevilla 
et al., 2013). Altogether, these antecedents made plausible that both 
TFs collaborate to regulate expression of common genes in epidermal 
development.  
Among the genes identified as GR transcriptional targets in 
cultured keratinocytes, we focused our study on two genes that 
contained both GR and KLF binding sites, and that are involved in 
inflammation in other tissues, Tsc22d3/Gilz and Zfp36/Ttp 
(supplementary Table 1 and Figure 15).  
Tsc22d3/Gilz encodes a protein named GILZ, which has been 
reported to be an anti-inflammatory mediator in several cell types. The 
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mechanisms of action of GILZ to block inflammatory gene transcription 
include its interaction with NF-B, AP-1 and Raf-1, thus inhibiting the 
downstream MAPK pathway (Srinivasan and Janardhanam, 2011; 
Ayroldi and Riccardi, 2009). GILZ is known to have several isoforms. 
The GBSs identified in this study map 13251 bp downstream of 
transcriptional start site (TSS) of isoforms Gilz1 and Gilz3, and 71645 
bp downstream of TSS of Gilz2; these GBSs are separated by 6 bp of 
the KLF binding site (Figure 15). 
Zfp36 gene codes for the protein Tristetraproline (TTP), which 
regulates the expression of many pro-inflammatory cytokines, including 
IL-22 and IL-23, which are important in autoimmune and inflammatory 
diseases (Härdle et al., 2015; Molle et al., 2013). TTP exerts its anti-
inflammatory role by binding to RNAs that contain AU-rich elements and 
recruits enzymes that degrade RNA or avoids translation of mRNAs of 
pro-inflammatory genes, including Tnf-α (Brooks and Blackshear, 
2013). TTP activity is regulated by phosphorylation (Patial et al., 2016). 
Furthermore, TTP overexpression has been shown to have protective 
effects in immune inflammatory diseases (Patial et al., 2016). The 
GBSs identified in this study map 2732 bp downstream of TSS and are 
separated by 1 and 98 bp of the two KLF binding sites (Figure 15). 
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Figure 15. GREs and KLF sites present in Tsc22d3 (A) and Zfp36 (B) 
genomic sequences bound by GR. Genomic sequences near Tsc22d3 and 
Zfp36 where GR was bound in ChIP-seq. GREs and adjacent KLF and AP-1 
sites are underlined. GR-bound peaks are denoted by asterisks in Tsc22d3 (A) 
or Zfp36 (B). Genome build: NCBI37/mm9. 
1.3. GR and KLF4 bound on Tsc22d3 and Zfp36 after 
Dex induction in immortal adult mouse keratinocytes 
  
Like any other primary cells, MPKs also have some restrictions, 
such as limited lifespan and low transfection efficiency. Hence, we 
decided to use an immortalized keratinocyte cell line from adult mouse 
epidermis, which was previously established and characterized in our 
group (Latorre et al., 2013). We first confirmed that there were no 
differences between the primary and immortalized keratinocytes due to 
the variability and differences that may be present in the basic biology 
of keratinocytes according to their stage of development and their 
status (primary or immortalized) (Yano and Okochi, 2005). 
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For this purpose, we first compared the GR recruitment and 
subsequent gene expression changes elicited by Dex treatment in both 
primary and immortal keratinocyte cell lines.  
 
Our data confirmed that GR was recruited to the regulatory 
sequences of Tsc22d3 and Zfp36 in the established keratinocyte cell 
line (Figure 16). Accordingly, Tsc22d3 and Zfp36 mRNA levels were 
significantly induced after Dex treatment (5.2-fold, and 1.6-fold, 
respectively) in this cell line (Figure 17). No significant differences were 
observed between the primary and immortalized cells regarding GR 
recruitment and expression of Tsc22d3 and Zfp36 after Dex treatment 
(Figure 16 versus Figure 13 and Figure 17 versus Figure 14), This 
indicates that the developmental stage and status of epidermal 
keratinocytes (primary or immortalized) did not influence the relative 
expression levels of the genes Tsc22d3 and Zfp36 or their induction by 
GCs.  
 
Figure 16. Dex induces similar GR binding to Tsc22d3 and Zfp36 in an 
immortal adult mouse keratinocyte cell line. Dex (100 nM) treatment for 2 h 
in an immortal adult mouse keratinocyte cell line induced recruitment of GR to 
putative regulatory sequences of Tsc22d3 and Zfp36 after ChIP-QPCR. Mean 
values ± SD show fold GR recruitment in Dex- versus mock-treated cells. 
Statistically significant differences between groups are indicated by asterisks 
(Student’s t-test, n = 4; *p < 0.05, **p < 0.01). 
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To evaluate whether the induction of Tsc22d3 and Zfp36 by Dex is 
strictly dependent on GR, we used an immortalized adult keratinocyte 
cell line deficient in GR, or GREKO cells (Latorre et al., 2013).  
 
 
Figure 17. Tsc22d3 and Zfp36 expression is not regulated by Dex in an 
adult mouse keratinocyte cell line deficient for GR (GREKO). Tsc22d3 and 
Zfp36 mRNA levels after Dex treatment (100 nM, 3 h) were assessed in GREKO 
and control (CO) cell lines by RT-QPCR. Mean values ± SD show relative gene 
expression in Dex- versus mock-treated samples. Statistically significant 
differences between groups are indicated by asterisks (Student’s t-test; n = 3; 
*p < 0.05; **p < 0.01). Representative immunoblotting showing lack of GR in 
GREKO relative to CO keratinocytes. Tubulin was used as a loading control. 
We analyzed the expression of Tsc22d3 and Zfp36 mRNA levels 
in control (CO) and GREKO cells treated with either vehicle or Dex for     
3 h (Figure 17). The lack of induction of both Tsc22d3 and Zfp36 in the 
GREKO cells indicates that the GR function is indispensable for the 
induction of both genes by Dex (Figure 6). Similar to GREKO 
keratinocytes, it was reported that specific deletion of GR in 
cardiomyocytes led to a lack of Zfp36 and Lipocalin2 induction (Sacta 
et al., 2016) in response to Dex (6 h). 
 
Next, we evaluated whether KLF4 was recruited to the identified 
Tsc22d3 and Zfp36 regulatory regions by ChIP-QPCR in the control 
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keratinocyte cell line. ChIP-QPCR using an anti-KLF4 antibody showed 
that Dex treatment induced significant KLF4 binding to both sequences 
(4.7-fold and 2.9-fold, respectively) (Figure 18, CO).  
 
Figure 18. Dex induces binding of KLF4 to Tsc22d3 and Zfp36 in immortal 
adult mouse keratinocytes. KLF4 was recruited to regions near Tsc22d3 and 
Zfp36 and increased upon Dex treatment (100 nM, 2 h) in CO but not in GREKO 
cells. Mean values ± SD show fold GR recruitment in Dex- versus mock-treated 
CO and GREKO cells. Statistically significant differences between groups are 
indicated by asterisks (Student’s t-test; n = 4; *p < 0.05; **p < 0.01). For 
Tsc22d3, there was a decrease between Dex-treated CO and GREKO, although 
it did not reach statistical significance (p=0.09).  
 
However, in GREKO keratinocytes, the Dex-induced recruitment of 
KLF4 to Tsc22d3 decreased by 2-fold compared to CO cells although 
it did not reach statistical significance (p=0.09). In the case of Zfp36, 
the recruitment of KLF4 in the absence (0.22-fold) and presence (0.39-
fold) of Dex was greatly and significantly reduced in the GR-deficient 
cell line relative to CO cells (Figure 18). Therefore the recruitment of 
KLF4 to Tsc22d3 and Zfp36 genomic regions containing both GR and 
KLF binding sites after Dex treatment suggests cooperation between 
these TFs in regulating these anti-inflammatory genes. 
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1.4. Evaluation of the response to Dex of Tsc22d3 and 
Zfp36 after Klf4 knockdown  
 
To further evaluate the contribution of KLF4 to the expression of 
Tsc22d3 and Zfp36 and their regulation by GCs, we performed Klf4 
knockdown assays in keratinocytes. KLF4 expression was decreased 
by approximately 70% at the RNA and protein level after transfection of 
the keratinocyte CO cell line with siRNA specific for Klf4 (Figure 19). 
Interestingly, GR protein levels were not affected by the Klf4 knockdown 
(Figure 19A), suggesting that KLF4 is not required for constitutive 
expression of GR. The induction of Tsc22d3 by Dex was decreased by 
approximately 2-fold in cells expressing the Klf4 siRNA relative to 
control siRNA (Figure 19B) demonstrating that both GR and KLF4 are 
required for proper transcriptional responses to GCs. 
 
 
Figure 19. Knockdown of Klf4 interferes with Dex-induction of Tsc22d3. 
A) Representative immunoblotting showing the expression of KLF4 in 
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keratinocytes transfected with control and Klf4 siRNA. Klf4 knockdown did not 
alter the GR expression. Tubulin was used as a loading control. B) Dex (100 
nM, 3 h) induced a significant increase in Tsc22d3 and Zfp36 in cells 
transfected with control but not Klf4 siRNAs as shown by RT-QPCR. Mean 
values ± SD show fold change in expression relative to mock-treated control 
siRNA transfectants. Statistically significant differences between groups are 
indicated by asterisks (Student’s t-test; n = 4; *p < 0.05; **p < 0.01). 
 
In contrast, Zfp36 was still induced in the Klf4 knockdown cells 
(Figure 19B). This could be due to the fact that Zfp36 would require a 
complete Klf4 knockdown or that KLF4 regulates this gene differently. 
Furthermore, KLF4 is required for Zfp36 induction as we observe 
recruitment of KLF4 in presence of Dex to Zpf36, and this recruitment 
is decreased in the absence of GR (Figure 18). 
 
1.5. Assessment of direct functional associations 
between GR and KLF4 
 
Whether or not GCs regulate the Klf4 gene expression in 
epidermal keratinocytes is still a controversy. According to a published 
microarray in cultured human keratinocytes, Dex induced Klf4 
expression 2-fold after 4 h, but not at 1 or 24 h (Stojadinovic et al., 
2007). However, no up-regulation was observed after an antenatal GC 
treatment in developing mouse skin (Patel et al., 2006). 
 
We evaluated the basal levels of Klf4 gene expression in 
immortalized cultured keratinocytes by RT-QPCR. Although Klf4 mRNA 
expression levels decreased in GREKO versus CO cells (Figure 20), no 
Klf4 induction was observed in CO keratinocytes treated with Dex for    
3 h (Figure 19B).  
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Figure 20. Reduced expression of Klf4 in GREKO relative to CO 
keratinocytes. Klf4 mRNA expression was determined by RT-QPCR. Mean 
values ± SD are shown, with asterisks denoting statistically significant 
differences in GREKO relative to CO (Student's t-test; n = 3; *p<0.05). 
 
We evaluated the levels of Klf4 mRNA in adult immortalized mouse 
keratinocytes after Dex treatment at additional time points (30 min, 1 h 
and 3 h).  
 
 
 
Figure 21. No changes of Klf4 mRNA levels in response to Dex at different 
time points. Adult immortalized mouse keratinocytes were treated with Dex 
100 nM at different time points (30 min, 1 h and 3 h) and Klf4 was determined 
by RT-QPCR. Mean values ± SD are shown. n=3. 
 
We did not observe changes in the regulation of Klf4 by Dex 
(figure 21), consistent with the results observed by Patel (Patel et al., 
2006). However, recent experiments in macrophages and also in 
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human cultured keratinocytes showed an induction of Klf4 in response 
to Dex (Chinenov et al., 2014; Stojadinovic et al., 2007). This suggests 
that the induction of Klf4 by Dex may be cell-type specific, as it is 
induced in macrophages (cells of the immune system) but not in mouse 
keratinocytes or in vivo. 
 
1.5.1. GR ChIP to assess binding at putative Klf4 
regulatory regions 
 
While these experiments were ongoing, Chinenov reported that in 
macrophages Dex induced GR recruitment to GBSs near Klf4 sites in 
Klf4 gene. These authors identified two putative GREs located at −3830 
bp and +5896 bp relative to the Klf4 TSS (Chinenov et al., 2014). In 
order to evaluate whether recruitment to this genomic region near Klf4 
also occurred in keratinocytes, we performed GR ChIP-QPCR using the 
reported primers flanking this region. Primers specific for a GBS near 
Tsc22d3 were used as a positive control. 
 
We did not observe GR recruitment to the aforementioned 
genomic regions in Klf4 in the presence of Dex, suggesting cell-type 
specific events likely due to expression of distinct co-regulators (Figure 
22).  
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Figure 22. Dex does not induce GR recruitment to the genomic regions of 
Klf4 in MPKs. After GR ChIP was carried out in MPKs treated with vehicle or 
Dex for 2 h.Then QPCR was performed using primers specific for genomic 
binding regions identified in our ChIP-Seq near Klf4 (Klf4Ch) or for a putative 
GRE near Klf4 identified in experiments with mouse macrophages (Klf4 GRE1; 
Chinenov et al., 2014). Primers specific for a GBS near Tsc22d3 were used as 
a positive control. 
We next assessed the direct interaction between GR and KLF4 
after Dex treatment (Figure 23). To address this, CO keratinocytes 
were treated with Dex for 0, 30 or 60 min, then cells were lysed and 
immunoprecipitated with antibody specific for KLF4 or a nonspecific 
rabbit IgG (RIgG) (t0). Input controls and immunoprecipitates were 
analyzed by immunoblotting with GR, p-GR and KLF4 antibodies. 
 
Figure 23. Dex treatment does not increase the direct interaction between 
GR and KLF4 in keratinocytes. Assessment of GR-KLF4 interaction via co-
immunoprecipitation. Cells treated with Dex for 0, 30 or 60 min were lysed and 
immunoprecipitated with antibody specific for KLF4 or a nonspecific rabbit IgG 
(t0). Input controls and immunoprecipitates were analyzed by immunoblotting 
with GR, p-GR and KLF4 antibodies. 
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The amount of GR in KLF4 immunoprecipitates was almost 
undetectable either in the absence or presence of Dex treatment, 
suggesting that there was no direct protein-protein interaction between 
these TFs (Figure 23). Although we assayed different technical 
conditions, it is also feasible that optimized conditions are required to 
detect this interaction. It is also possible that KLF4 recruitment 
facilitates the GR recruitment to their regulatory sequences promoting 
the chromatin accessibility as described for TF C/EBPβ in liver 
(Grontved et al., 2013).  
 
1.6. Klf4, Zfp36, and Tsc22d3 up-regulation during in 
vitro keratinocyte differentiation depends on GR 
 
As mentioned in the introduction, the keratinocytes of the 
epidermis undergo constant renewal and go from the more basal layers 
through the suprabasal layers following the terminal differentiation.  
 
A proper keratinocyte terminal differentiation is important for a 
correct function of the skin and anomalies in this process correlate with 
several inflammatory skin diseases, including atopic dermatitis and 
psoriasis (Guttman-Yassky et al., 2017). During terminal differentiation 
GR, Klf4, Tsc22d3 and Zfp36 are up-regulated (Sen et al., 2010; Yoon 
et al., 2014). Furthermore, both Tsc22d3 and Zfp36 are known to be 
induced by Dex in human keratinocytes (Stojadinovic et al., 2007). This 
suggests possible involvement of the Tsc22d3 and Zfp36 in 
keratinocyte differentiation process. However, the function and 
regulation of these genes in the epidermis has not been extensively 
studied.  
 
We evaluated whether Tsc22d3 and Zfp36 required GR for their 
induction in keratinocyte differentiation. For this purpose we evaluated 
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the changes in the expression of Zfp36 and Tsc22d3 in wild type and 
GR-deficient keratinocytes under high calcium conditions (1.2 mM) for 
0 and 72 h (Figure 24), a well-known method to stimulate keratinocyte 
differentiation in vitro (Hennings et al., 1980). This method resembles 
the in vivo gradient of calcium in the epidermis with low levels in the 
basal layer and high levels in the suprabasal layers.  
 
Figure 24. Absence of GR (GREKO cell line) provoked a deficient calcium-
induced differentiation. A) Representative microphotographs showing 
differential features in morphology after differentiation induced by 1.2 mM 
calcium for 72 h in CO and GREKO cells. Cornified envelopes are present in CO 
cells as indicated by asterisks, but not in GREKO cells. Scale bar: 50 μm.               
B) Gene expression of Sprr2d, Nr3c1, Klf4, Tsc22d3, and Zfp36 in CO or GREKO 
cells treated for 0 or 72 h with 1.2 mM calcium was assessed by RT-QPCR. 
Mean values ± SD show changes in gene expression relative to t0. Statistically 
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significant differences relative to untreated controls are indicated by asterisks 
(Student’s t-test; n = 4; *p < 0.05; **p < 0.01). The graph has a logarithmic scale.  
 
In the presence of high calcium (1.2 mM), CO keratinocytes 
underwent terminal differentiation as observed by the morphological 
changes. CO cells displayed flattening, extensive cell–cell contacts, 
stratification and formation of cornified envelopes (Figure 24A; 
asterisks). However, GREKO cells exhibit defective terminal 
differentiation as shown by an aberrant morphology featuring a spindle-
like phenotype with decreased cell–cell contacts in normal calcium 
conditions (Figure 24A) and after high calcium, GREKO cells also lacked 
cornified envelopes (Figure 24A). In addition, in order to allow 
quantification of differentiation we evaluated the mRNA expression of 
the late differentiation marker Sprr2d (Small Proline Rich Protein 2D), 
which is an important constituent of the cornified envelope in the skin 
and known to be induced by calcium and regulated by GR (Jackson et 
al., 2005; Pérez, 2011). Sprr2d was strongly induced in calcium-treated 
CO but not in GREKO cells, as shown by RT-QPCR (Figure 24B), 
confirming impaired cell differentiation in the absence of GR. 
 
We next examined whether the mRNA levels of Nr3c1/GR and Klf4 
changed in high calcium conditions. Although Nr3c1 mRNA levels were 
not increased in calcium-treated CO cells, (Figure 24B) GR protein 
levels increased moderately (Figure 29), which is in line with the results 
reported by Yoon and colleagues (Yoon et al., 2014). As mentioned 
above and as expected, Klf4 mRNA and protein were up-regulated in 
calcium-treated CO cells. However, in GREKO cells there was no 
significant expression of Klf4 in terminal differentiation-induced 
conditions (Figures 24B and 29). Induction of Klf4 is a requirement for 
keratinocyte terminal differentiation (Segre et al., 1999). Thus, the non-
appropriate response to calcium-induced terminal differentiation in 
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GREKO cells may be a consequence of both the absence of GR and the 
partial lack of Klf4. 
 
We also evaluated the levels of Tsc22d3 and Zfp36 under high 
calcium conditions. The mRNA levels expression of both genes 
increased during differentiation of CO cells (Figure 24B), which was 
consistent with published microarray data (Sen et al., 2012). On the 
other hand, high calcium medium in GREKO cells did not up-regulate 
Zfp36, whereas Tsc22d3 decreased 3-fold in induction relative to the 
CO (Figure 24B).  
 
The calcium-induced terminal differentiation experiments (Figure 
24) were performed with medium supplemented with serum containing 
endogenous corticosteroids. So, in order to corroborate that GR is 
necessary for terminal differentiation in CO keratinocytes, we incubated 
cells with 1.2 mM calcium in the absence or presence of the GR 
antagonist RU486 (also known as mifepristone) for 72 h (Figure 25). 
Cells treated with RU486 failed to properly differentiate, not only by a 
reduced number of cornified envelopes relative to vehicle-treated cells 
(Figure 25; asterisks), but also by a significant decreased expression 
of Sprr2d and Klf4 (Figure 25B). 
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Figure 25. The GR antagonist RU486 decreases the terminal 
differentiation induced by calcium in mouse CO keratinocytes. A) 
Representative microphotographs showing differential features in morphology 
after differentiation induced by 1.2 mM calcium for 72 h in CO and in presence 
of RU486 (1 µM, 6 h pretreatment). Cornified envelopes are present in CO cells 
as indicated by asterisks, but not in presence of RU486. Scale bar: 50 μm.         
B) The mRNA expression of Sprr2d and Klf4 in CO cell line treated with vehicle 
or RU486 under calcium-induced terminal differentiation was assessed by RT-
QPCR. Statistically significant differences between groups are indicated by 
asterisks (Student’s t-test; n = 4; *p < 0.05). 
 
TSC22D3/GILZ is known to be involved in inflammatory signaling 
response through direct binding to RAS and RAF-1 thus inhibiting the 
ERK downstream signaling. This inhibition of MAPK signaling in 
keratinocytes is relevant for stopping the inflammation and favoring 
differentiation (Tarutani et al., 2003). On the other hand, ZFP36 is 
responsible for destabilizing Tnf mRNA (Brooks and Blackshear, 2013) 
thus acting as an anti-inflammatory molecule. Furthermore, ZFP36 can 
also regulate a variety of additional cytokines involved in skin immunity 
and keratinocyte differentiation, as well as factors that can affect the 
cell cycle control, including Cyclin D1 (Brooks and Blackshear, 2013). 
Therefore, we hypothesize that the lack of up-regulation of Tsc22d3 and 
Zfp36 in the calcium-induced terminal differentiation in GREKO 
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keratinocytes could have an effect on both inflammatory signaling, as 
well as the process of differentiation.  
 
1.7. GR downregulates mRNA levels of distinct Trp63 
isoforms in keratinocytes   
 
Since Dex treatment did not alter Klf4 expression in cultured 
mouse keratinocytes (Figure 19B), we considered other mechanisms 
for its dysregulation during calcium-induced differentiation of GREKO 
cells.  
In our ChIP-seq datasets, we found also a genomic region peak 
near Trp63 gene, which maps to chromosome 16. Trp63 is an important 
master regulator of the epidermis since it encodes p63, a TF necessary 
for the development and homeostasis of the skin. (Yang et al., 1999). 
 
Figure 26. Genomic region peak near Trp63. Evaluation of GR binding to 
genomic regions near Trp63. A. Screenshot of peak (red asterisk) which lies in 
between Trpg and Trp63 genes. 
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Figure 27. GR recruitment to genomic region near Trp63. MPKs were 
incubated with Dex 100 nM for 2 h. GR recruitment to the genomic region near 
Trp63 was determined by ChIP followed by QPCR (n=4, Student’s t-test, ** 
p<0.01). 
 
We found a high GR recruitment (around 18-fold) to the genomic 
region near Trp63 after Dex treatment (100 nM, 2 h). 
 
Trp63 encodes for two isoforms either containing (TAp63) or 
lacking (ΔNp63) the N-terminal transactivation domain. The 
predominant isoform of Trp63 in the epidermis is ΔNp63 (Melino, 2011). 
GR is a known repressor of ΔNp63, as mice overexpressing GR in 
epidermal keratinocytes present low levels of ΔNp63 (Cascallana et al., 
2005). Furthermore, it has been shown that ΔNp63 represses Klf4 
expression by directly binding to its promoter (Cordani et al., 2011), and 
both ΔNp63 and KLF4 have different patterns of expression in the 
epidermis, as ΔNp63 is detected in the basal layer, whereas KLF4 is 
expressed suprabasally.  
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Figure 28. Dex repressed expression of Trp63 isoforms ΔNp63 and TAp63 
in CO but not in GREKO cells. The mRNA levels were assessed by RT-QPCR 
after Dex treatment (100 nM, 3h). Mean values ± SD are shown. Statistically 
significant differences relative to mock-treated (V) CO cells are denoted by 
asterisks (Student’s t-test; n = 3; *p < 0.05; **p < 0.01). 
 
We assessed whether Dex-activated GR could modulate Klf4 
expression through the control of Trp63. First, we assessed the mRNA 
levels of Trp63 isoforms, ΔNp63 and TAp63, in CO and GREKO cell lines 
(Figure 28). Dex treatment downregulated the mRNA levels of both 
genes in CO keratinocytes, however, no effect was observed in GREKO 
cells (Figure 28), suggesting that Dex-activated GR may inhibit their 
expression. It is noteworthy, that TAp63 levels were increased by 2-fold 
in GREKO relative to CO keratinocytes (Figure 28). It has been reported 
the role of TAp63 as a tumor suppressor (Vanbokhoven et al., 2011), 
whereas inducible epidermal overexpression results in 
hyperproliferation and deficient terminal differentiation (Koster et al., 
2006). This discrepancy may be due to different functions depending 
on cellular context.  
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1.8. Impaired regulation of p63 and KLF4 during 
calcium-induced terminal differentiation 
 
Next, we evaluated the protein levels of GR, KLF4 and ΔNp63 by 
using immunoblotting. We assessed the levels of the isoform ΔNp63, 
as the predominant p63 protein isoform detected in keratinocytes by 
immunoblotting (Truong et al., 2006), whereas TAp63 is expressed at 
low levels in this tissue and is difficult to detect (Melino, 2011). 
 
 
Figure 29. Impaired regulation of p63 and KLF4 during calcium-induced 
terminal differentiation. Representative immunoblotting (left panel). Tubulin 
was used as a loading control. Quantification of immunoblotting experiments. 
Mean values ± SD are shown, with asterisks denoting statistically significant 
differences relative to CO at t0 (Student’s t-test; n = 4; *p < 0.05; **p < 0.01).  
 
We observed a small increase of ΔNp63 in calcium-induced 
differentiated CO keratinocytes (Figure 29, 1.6-fold). In undifferentiated 
GREKO cells, ΔNp63 protein levels were up-regulated 1.8-fold relative to 
CO and these levels were further increased (5-fold) after high calcium 
treatment (Figure 29).  
 
These results suggest that the presence of GR is necessary for the 
appropriate levels of KLF4 and results in inhibition of p63. Furthermore, 
the lack of induction of Klf4 shown in Figure 24 during calcium-induced 
Results and Discussion 
 
92 
 
differentiation in GREKO cells is likely an indirect effect of the loss of GR 
expression, such as the proposed negative regulation by p63. 
 
Although KLF4 was known to interfere with inflammatory signaling 
pathways in immune cells such as macrophages (Chinenov et al., 
2014), the GR/KLF4 interaction was not previously studied in 
keratinocytes. Our results demonstrate a direct cooperation between 
GR and KLF4 in the regulation of the anti-inflammatory genes such as 
Tsc22d3 and Zfp36 expression in keratinocytes by binding at their 
genomic regulatory regions.  
 
1.9. GR downregulates mRNA levels of distinct Trp63 
isoforms during keratinocyte differentiation  
 
We next evaluated the expression of both Trp63 isoforms in CO 
and GREKO keratinocytes during calcium-induced terminal 
differentiation (Figure 30). 
 
 
Figure 30. Increased expression of ΔNp63 and TAp63 isoforms during 
calcium-induced terminal differentiation in GREKO versus CO cells. 
Relative mRNA levels were assessed by RT-QPCR. Mean values ± SD are 
shown. Statistically significant differences relative to CO at t0 are represented 
by asterisks (Student’s t-test; n = 3; *p < 0.05; **p < 0.01).  
Results and discussion 
 
93 
 
The mRNA expression of both ΔNp63 and TAp63 transcripts did 
not change after calcium-induced differentiation in CO cells, whereas 
the expression of both transcripts was up-regulated in GREKO cells 
relative to CO cells at t0 by 1.8- and 6.6-fold, respectively. Furthermore, 
in calcium-induced differentiation, ΔNp63 expression was up-regulated 
3-fold in GREKO cells, whereas TAp63 expression did not change 
significantly in the GREKO cells treated with calcium (Figure 30). 
 
Note that these basal levels differ from those shown in the previous 
experiment (Figure 28), which can be explained by the use of complete 
serum in the calcium experiments instead of charcoal-stripped serum 
used for the Dex treatments. This suggests that other lipophilic 
compounds present in the serum participate in the basal regulation of 
Trp63 isoforms.  
 
Finally, we present a model that summarizes the ideas obtained in 
the first part of the dissertation (Figure 31). 
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Figure 31. GR and KLF4 are necessary for proper expression and 
regulation of Gilz/Tsc22d3 and Zfp36 in epidermal keratinocytes. Left: In 
keratinocytes, GR and KLF4 bind to adjacent regulatory sequences of 
Gilz/Tsc22d3 and Zfp36 and coordinately induce gene expression in response 
to Dex or calcium. GR transcriptionally represses p63, an inhibitor of KLF4 
expression, and thus indirectly modulates KLF4 under various conditions. 
Right: In the absence of GR, p63 expression increases while KLF4 expression 
is decreased. Altogether, lack of GR along with reduced KLF4 results in 
inappropriate Gilz/Tsc22d3 and Zfp36 gene expression in response to Dex or 
calcium. 
 
 
 
 
 
 
  
 
 
Part II 
Functional analysis of GILZ in transgenic 
mice with generalized overexpression: 
implications in psoriasis 
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Previous studies have shown the role of GILZ as an anti-
inflammatory mediator in several mouse models of pathologies 
(Cannarile et al., 2009, Pinheiro et al., 2013, Esposito et al., 2012, 
Srinivasan and Janardhanam, 2011). These studies postulate that GILZ 
can exert the same anti-inflammatory and immunosuppressive effects 
as the GCs, without having their associated side effects. Thus, it has 
been suggested that GILZ could be used as a potential therapeutic tool 
in various inflammatory diseases (Ronchetti et al., 2015). However, the 
role of GILZ in the pathophysiology of the skin is poorly studied. We 
previously described that GCs induce Gilz mRNA expression in 
epidermal keratinocytes by direct recruitment of GR to Gilz regulatory 
sequences (Part I of this dissertation). As GILZ is an anti-inflammatory 
mediator in other cell types, we decided to study the effects of GILZ 
using transgenic mice with generalized overexpression of this protein 
(Prof. Libert, University of Ghent) and the imiquimod (IMQ) mouse 
model of psoriasis. 
 
Tsc22d3/Gilz has 4 different isoforms, among them, Gilz1 and 
Gilz2 (Soundararajan et al., 2007). In our experiments, we observed 
that both Gilz1 and Gilz2 are induced by Dex (100 nM for 3 h) in adult 
mouse immortal keratinocytes by 8.7- and 4.1-fold, respectively (Figure 
32).  
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Figure 32. Gilz1 and Gilz2 isoforms are induced upon Dex treatment. 
Immortal mouse adult keratinocytes were treated with Dex 100 nM for 3 h and  
mRNA expression of Gilz isoforms (Gilz1 and Gilz2) was assessed by RT-
QPCR (n=3). 
 
In contrast, Gilz1 and Gilz2 showed a different response to 
calcium-induced keratinocyte differentiation (1.2 mM calcium for 72 h). 
While Gilz1 mRNA expression decreased weakly (1.3-fold) although 
significantly after calcium treatment, Gilz2 was up-regulated by around 
3-fold. Although some studies addressed the different functions of GILZ 
isoforms in the regulation of proliferation and ion transport 
(Soundararajan et al., 2007), there is little knowledge regarding the 
differential regulation of distinct isoforms. Understanding the cell-type 
specific regulation of GILZ isoforms would require further research.  
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Figure 33. Regulation of Gilz1/Gilz2 isoforms in keratinocytes in response 
to calcium-induced differentiation. Immortal mouse adult keratinocytes were 
treated with high calcium concentration (1.2 mM for 72 h) to induce terminal 
keratinocyte differentiation. The mRNA expression of Gilz isoforms (Gilz1/Gilz 
2) was assessed by RT-QPCR (n=3; Post hoc Tukey test *p<0.05; **p<0.01). 
 
 
2.1. Mice with generalized overexpression of GILZ 
(GILZ-Tg) 
For the following in vivo experiments, we have used mice with 
generalized overexpression of the GILZ1 isoform (GILZ-Tg), the 
canonical and most widely studied. GILZ-Tg mice were generated as 
described in Material & Methods (Figure 34). Mice with the same 
genetic background as the GILZ-Tg mice were used as control mice 
(GILZ-Wt). 
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Figure 34. Generation of mice overexpressing GILZ (GILZ-Tg mice). 
Scheme of the transgene construct. Conditional GILZ-Tg overexpressing mice 
were generated by knocking in the mouse Tsc22d3/Gilz-1 cDNA preceded by 
a loxP flanked stop cassette under control of the ROSA26 promoter, using a 
Gateway-compatible ROSA26 locus targeting vector. Mice homozygous for the 
loxP flanked stop cassette and one allele of Nestin-cre, expressing Cre in all 
cell types, were generated by crossing. 
We first determined the relative expression of GILZ at the mRNA 
and protein level in several tissues of GILZ-Tg mice. The skin of        
GILZ-Tg mice showed a relative increase of expression both at the 
mRNA and protein levels ranging between 3- and 8-fold in comparison 
to GILZ-Wt (Figure 35). Significant increases of GILZ (mRNA and 
protein level) in spleen and bone marrow-derived macrophages of 
GILZ-Tg relative to GILZ-WT mice ranged between 3- and 6-fold 
(Figure 35), and confirmed the generalized overexpression of GILZ in 
this transgenic mouse model. 
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Figure 35. Relative Tsc22d3/Gilz mRNA and protein levels in GILZ-Tg 
versus GILZ-Wt mice. Relative mRNA levels of Tsc22d3/Gilz in skin, spleen 
and bone marrow-derived macrophages were determined by RT-QPCR and 
relative protein levels by Western blot. Tubulin was used as a loading control. 
Mean values ± SD are shown. Statistically significant differences relative to 
controls are denoted by asterisks (Student’s t test; n = at least 3 per genotype; 
*p <0.05; ***p<0.001).  
2.1.1. Phenotypic characterization of the skin in GILZ-
Tg mice 
 
To evaluate whether the overexpression of GILZ may affect the 
skin architecture, we examined skin sections of newborn (P0) and adult 
GILZ-Tg and GILZ-Wt mice by hematoxylin and eosin (H&E) staining. 
Newborn GILZ-Tg mice were viable and did not show any macroscopic 
abnormalities relative to control newborn mice. Skin sections from 
newborn and adult GILZ-Tg mice stained with H&E did not reflect any 
impairment in their architecture as compared to control mice (GILZ-Wt) 
(Figures 36 and 37).   
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Figure 36. GILZ-Tg newborn mice show normal skin architecture. 
Representative H&E stained sections of newborn mouse skin of GILZ-Wt and 
GILZ-Tg mice (n=10 per genotype) at day of birth (P0). Brackets separate 
epidermis from dermis and hair follicle is denoted by asterisks. Scale bar:           
50 µm. 
 
 
Figure 37. GILZ-Tg adult mice show normal skin architecture. 
Representative H&E stained sections of the adult mouse skin of GILZ-Wt and 
GILZ-Tg mice showing no major differences in tissue architecture (n=5 per 
genotype). Scale bar: 50 µm. 
2.2. GILZ increases IMQ-induced psoriasis-like skin 
lesions in adult mice 
 
To evaluate the implication of the overexpression of GILZ in 
psoriasis, GILZ-Tg mice were subjected to the IMQ-induced mouse 
model. 
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The IMQ-induced psoriasis-like mouse model was first described 
by Van der Fits and colleagues (Van der Fits et al., 2009). IMQ is an 
agonist of the TLR 7/8 and is used topically in the formulation of a cream 
named Aldara®, which contains 5% of IMQ. We topically applied 
Aldara® on shaved mouse dorsal skin daily for 7 days, which led to a 
macroscopic phenotype resembling human psoriasis. The kinetics and 
severity of the IMQ response were assessed in both GILZ-Tg and     
GILZ-Wt mice, as described below. 
 
Macroscopically, we daily scored erythema (redness) and scaling 
(desquamation) of both genotypes upon IMQ treatment for the whole 
duration of the experiment (Figure 38). GILZ-Tg mice displayed a more 
pronounced response to IMQ treatment compared to GILZ-Wt mice 
consisting in increased skin erythema (Figure 38, asterisks) and more 
severe desquamation (Figure 38, arrows). These differences were 
more marked from day 4 onwards until the end point of the IMQ 
experiment (Figure 38). 
 
                                            
Figure 38. GILZ-Tg mice show increased psoriatic features in response to 
IMQ. Left panel: Score of the erythema and scaling in GILZ-Wt and GILZ-Tg 
for the duration of the experiment. Right panel: Macroscopic appearance of 
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GILZ-Wt and GILZ-Tg mice treated with IMQ at day 7. Mean values ± SD are 
shown. Post hoc Tukey test ***p<0.001, n=at least 5 per genotype and 
treatment. 
Although GILZ has been reported to act as an anti-inflammatory 
therapeutic protein in various animal models of inflammatory diseases 
(Cannarile et al., 2009; Ngo et al., 2013a), the overexpression of GILZ 
in other cells has been shown to be contrary to the expected results. 
For example, continuous GC treatment induces adipocyte 
differentiation by activating the adipogenic peroxisome-proliferator-
activated receptor-γ2 (PPAR-γ2) promoter. In contrast, overexpression 
of GILZ inhibits PPAR-γ2 transcriptional activation, thus blocking 
adipocyte differentiation (Shi et al., 2007). GILZ has also been reported 
to be associated with other GC-induced side effects, such as the 
inhibition of the repair of respiratory epithelial cells (Liu et al., 2013). 
We may speculate that high levels of exogenous GILZ also cause 
side effects in skin, similar to those reported in chronic GC 
treatments. Further experiments assessing GILZ expression in skin 
after continuous GC exposure may help to understand this issue.   
 
As we have studied the effects of the overexpression of the GILZ1 
isoform, it could be possible that a misbalance between the isoforms, 
for example, GILZ1 and GILZ2 isoforms may also contribute to a pro-
inflammatory phenotype.  
2.2.1. Histopathological assessment of GILZ-Tg mouse 
skin after IMQ-induced psoriasiform lesions 
 
To examine the morphological differences between the IMQ-
treated GILZ-Wt and GILZ-Tg mice we initially performed a 
histopathological assessment of the skin samples at day 7 by H&E 
staining. The H&E-stained control skin sections displayed the 
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characteristic features of the IMQ treatment that included epidermal 
thickening (acanthosis) and thickening of the stratum corneum 
(hyperkeratosis) relative to vehicle-treated groups (Figure 39, left). 
However, IMQ-treated GILZ-Tg mice displayed even more pronounced 
features in terms of epidermal thickening, hyperkeratosis, as well as 
increased dermal cellularity in comparison to GILZ-Wt mice (Figure 39, 
left). 
 
In GILZ-Tg mice, the more severe lesions also included increased 
epidermal protrusions (rete-ridges), abnormal keratinocyte 
differentiation with retention of the nuclei in the stratum corneum 
(incomplete cornification), the outermost layer of the epidermis 
(parakeratosis), and neutrophil infiltration (Munro-like abscess) 
(Wagner et al., 2010). 
 
 
Figure 39. Histological characterization of adult GILZ-Wt and GILZ-Tg 
mouse skin sections after IMQ treatment. Left panel: H&E stained skin 
sections: Epidermal thickening is denoted by brackets; hyperkeratosis by 
asterisks; abnormal differentiation with parakeratosis by thick arrows, and 
epidermal infiltrate (Munro-like abscess) by thin arrowhead. Right panel: 
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immunostaining with keratin 6 (K6), Loricrin (LOR), and Caspase-14 (CASP-
14) antibodies. Scale bar: 50 µm. Samples from two independent experiments 
were assessed (n= 15 GILZ-Wt, n= 16 GILZ-Tg). 
 
Although mouse skin normally does not present rete-ridges, 
repeated treatment with IMQ can induce their formation (Lawlor and 
Kaur, 2015). 
 
Next, we assessed the expression of keratin 6 (K6), an epithelial 
marker whose expression is normally restricted to hair follicles and 
absent in the interfollicular epidermis of adult mouse skin. However, K6 
expression is up-regulated during pathophysiological skin conditions 
including hyperproliferative states (Haines and Lane, 2012). 
Immunostaining of skin sections showed that K6 was present in the 
upper layers of the epidermis of both IMQ-treated GILZ-Wt and       
GILZ-Tg mice, besides the hair follicles (Figure 39, K6). We also 
evaluated the expression of loricrin (LOR), a terminal differentiation 
marker that is present in the upper layers of the epidermis and 
constitutes the 80% of the cornified envelope (Segre, 2003). In IMQ-
treated GILZ-Wt mice, loricrin was restricted to the upper differentiated 
layers of the epidermis, however, in GILZ-Tg mice, this marker was 
focally absent correlating with augmented parakeratosis (Figure 39, 
LOR; denoted by black arrows). 
 
This parakeratosis or aberrant cornification resulting in the 
accumulation of nuclei in the outermost epidermal layer may be 
produced by several mechanisms (Denecker et al., 2008). One 
mechanism includes impaired expression or function of Caspase-14 
(CASP-14). CASP-14 is the only non-apoptotic epidermal-specific 
protease which is confined to the suprabasal layers of the epidermis. It 
plays a key role in the epidermal barrier function as it has been reported 
to be involved in the terminal keratinocyte differentiation. It is activated 
in cornification and it normally induces the formation of mature filaggrin 
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and its degradation into free amino acids, thus providing a competent 
stratum corneum (Denecker et al., 2008; Hoste et al., 2011).     
Caspase-14 expression levels are low in human lesional psoriatic skin 
likely due to the action of T-helper type 2 cytokines (Denecker et al., 
2008; Hvid et al., 2011). It has been previously reported that CASP-14 
deficient mice were more predisposed to develop parakeratosis after 
IMQ treatment (Hoste et al., 2013). In our study, we observed that 
CASP-14 was expressed in the suprabasal layers of the GILZ-Wt mice 
skin after IMQ treatment (Figure 39, CASP-14 expression denoted by 
thin arrows), whereas it was absent in GILZ-Tg skin. Although this 
absence of expression coincided with the presence of areas with 
parakeratosis (Figure 39, parakeratosis denoted by thick arrows), the 
lack of CASP-14 is more likely to be a result of a defective epidermal 
barrier, rather than the cause of it. Thus, CASP-14 knockout mice did 
not show spontaneous parakeratosis but IMQ treatment induced 
increased parakeratosis (Denecker et al., 2008). The link between GILZ 
and the modulation of CASP-14 is still unknown. However, it is possible 
that the reduced expression of CASP-14 in GILZ-Tg skin may be due 
to the fact that other TFs responsible for the regulation of epidermal 
differentiation are altered due to ectopic or augmented expression of 
GILZ (Denecker et al., 2008).  
 
2.2.2. Molecular changes in the skin of GILZ-Tg mice 
after IMQ treatment  
 
It has been reported that GILZ is down-regulated by several 
inflammatory stimuli such as inflammatory cytokines IL-1, TNF-α and 
IFN-γ in human airway epithelial cells further contributing to the 
inflammatory process (Ayroldi and Riccardi, 2009). We thus evaluated 
the relative mRNA levels of Tsc22d3/Gilz upon the IMQ treatment. In 
GILZ-Wt skin, IMQ down-regulated the expression of endogenous 
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Tsc22d3/Gilz mRNA around 60% while in GILZ-Tg skin, these levels 
remained high before and after the IMQ treatment (Figure 40). 
 
Figure 40. Determination of relative Tsc22d3/Gilz mRNA levels in skin 
from GILZ-Wt and GILZ-Tg treated with vehicle or IMQ at day 7 by RT-
QPCR. Mean values ± SD are shown. Post hoc Tukey test *, # p<0.05; 
***p<0.001, n=at least 5 per genotype and treatment. Asterisks: significance 
between treatments within each genotype; hashes: significance between 
genotypes in the same treatment group. 
However, note that the higher constitutive mRNA levels of 
Tsc22d3/Gilz in GILZ-Tg mice were further up-regulated by IMQ 
treatment probably due to the lack of regulatory sequences in the 
transgene construct (Figure 40). Importantly, the observed decrease of 
Tsc22d3/Gilz mRNA levels in IMQ-treated control skin correlated with 
the reported low Tsc22d3/Gilz levels found in human psoriatic lesions 
(Jones et al., 2015).  
 
In addition, the down-regulation (2.6-fold) of Tsc22d3/Gilz was 
reported in psoriatic human lesions vs non-lesional matched biopsies 
(Suárez-Fariñas et al., 2012). The Tsc22d3/Gilz down-regulation 
observed in IMQ-treated GILZ-Wt but not in GILZ-Tg skin (Figure 40) 
may suggest that GILZ down-regulation is necessary for the resolution 
of inflammation. However, the continuous expression of GILZ may 
produce effects different to the anti-inflammatory expected ones. It 
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would be possible that the constitutive GILZ overexpression may induce 
side effects, similar to the results of the continuous treatment with GC. 
2.2.3. Determination of cytokines related with psoriasis 
in GILZ-Tg skin  
 
Next, we assessed the mRNA expression of cytokines related to 
the IL-23/Th17 axis, as well as other inflammatory markers whose 
expression is found to be increased in human psoriasis and mouse 
psoriatic skin (Wagner et al., 2010; Flutter and Nestle, 2013). The 
expression of Il-17f and Il-22 mRNA levels (2.5- and 4-fold, 
respectively) increased significantly in IMQ-treated GILZ-Wt compared 
to the untreated GILZ-Wt mice. This induction was higher in GILZ-Tg 
mice. IL-22 has been shown to be involved in epidermal hyperplasia 
and production of antimicrobial peptides by keratinocytes in humans 
and mice, inducing plaque formation and protective skin function (Van 
Belle et al., 2012). Although Il-23 presented a tendency to increase in 
IMQ-treated GILZ-Wt mice, it was up-regulated in IMQ-treated GILZ-Tg 
mice (Figure 41). After IMQ treatment, cytokines were highly induced 
in GILZ-Tg mice relative to the IMQ-treated GILZ-Wt mice (Figure 41). 
 
Lesional psoriatic skin presents high levels of calcium-binding 
proteins S100A8/A9, which are expressed in keratinocytes and other 
immune cells such as neutrophils (Lee et al., 2012). Other inflammatory 
cytokines including IL-6 and STAT3 are also induced in human patients 
and mouse models of psoriasis (Johnson-Huang et al., 2012).  
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Figure 41. Up-regulation of inflammatory mediators in IMQ-treated GILZ-
Tg relative to GILZ-Wt mouse skin. Relative mRNA levels of the indicated 
genes were assessed by RT-QPCR in skin collected from the same individuals 
after IMQ treatment (7d). Mean values ± SD are shown. Post hoc Tukey test *, 
#p<0.05; **, ##p<0.01; ***, ###p<0.001; n=at least 5 per genotype and treatment. 
Asterisks: significance between treatments within each genotype; hashes: 
significance between genotypes in the same treatment group. 
STAT3 is a widely studied member of the Signal transducers and 
activators of transcription (STATs) family. Once STAT3 is activated 
through phosphorylation, form dimers and translocates to the nucleus 
transmitting extracellular signals to the nucleus. STAT3 has an 
important role in various biological activities, including cell proliferation, 
survival and cell migration. STAT3 activation in keratinocytes is 
essential for skin wound healing (Sano et al., 2005). Furthermore, the 
overexpression of STAT3 directed to epidermal keratinocytes produces 
features resembling psoriasis. 
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S100a8, S100a9, and Stat3 were significantly up-regulated in 
IMQ-treated GILZ-Wt mice (200, 70, and 1.6-fold, respectively) and 
these increases were even higher in IMQ-treated GILZ-Tg mice 
compared to IMQ-treated GILZ-Wt (Figure 41).  
2.2.4. Serum cytokines and immune cells in IMQ-
treated GILZ-Tg mice  
 
Besides the epidermal alterations and elevated serum cytokines, 
psoriasis is characterized by pronounced inflammatory infiltrates mainly 
consisting of T cells and dendritic cells, as well as neutrophils, 
mastocytes, and macrophages.  
 
We wondered whether the higher susceptibility observed in      
GILZ-Tg after IMQ treatment could be due to an increase in serum 
cytokines. To address this question we collected serum from IMQ-
treated GILZ-Tg and GILZ-Wt mice at different time points (0, 2, 4 and 
7 days) and assessed the levels of the cytokines IL-17A, IL-17F and 
TNF-α using Luminex technology (Bio-plex, Bio-Rad) (Figure 42). 
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Figure 42. Serum cytokines IL-17A, IL-17F and TNF-α did not contribute to 
the further susceptibility of GILZ-Tg mice to IMQ. Cytokines IL-17A, IL-17F 
and TNF-α were collected at different time-points of the IMQ experiment and 
measured by using Luminex technology (Bio-plex, Bio-Rad). Post hoc Tukey 
test **p<0.01; ***p<0.001; n=at least 3 per genotype and treatment.  
The indicated cytokines presented a peak of expression at days 2 
and 4 after IMQ treatment but no significant differences were found 
among genotypes, suggesting that serum cytokines are not responsible 
for the more severe phenotype in IMQ-treated GILZ-Tg mice. 
 
Also, GILZ-Tg IMQ-treated mice displayed increased dermal 
cellularity compared to GILZ-Wt mice, as observed in the H&E stained 
sections (Figure 39). 
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Figure 43. Distinct immune cell populations in skin did not contribute to 
the further susceptibility of GILZ-Tg mice to IMQ. Neutrophils, dendritic 
cells, CD4+ T cells and CD8+ T cells were isolated at day 7 of the IMQ 
experiment and measured by FACS. Post hoc Tukey test *p<0.05; **p<0.01; 
***p<0.001, n= 4 per genotype and treatment. Asterisks: significance between 
treatments within each genotype. 
In the IMQ mouse model of psoriasis, the number of immune cells 
is increased by the treatment and it contributes to the severity of the 
disease (Van der Fits et al., 2009). For this reason, we assessed 
different subpopulations of immune cells in the skin of IMQ-treated 
GILZ-Tg vs GILZ-Wt mice. To answer this question, we treated mouse 
ears of both genotypes with IMQ daily for up to 7 days and analyzed 
the composition of the isolated immune cells using flow cytometry 
(FACS). Although neutrophils, dendritic cells, CD4+T cells and CD8+ T 
cells showed a significant increase after IMQ treatment in both 
genotypes, this increment was not higher in GILZ-Tg compared to 
GILZ-Wt (Figure 43). Since T cells are not the only producers of IL-22 
and IL-17, we cannot rule out the contribution of other immune cells to 
the more impaired phenotype in the GILZ-Tg mice treated with IMQ and 
the increased levels of cytokines in the GILZ-Tg skin (Figure 41). 
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2.2.5. Systemic effects of topical imiquimod: impact in 
spleen and gut 
 
It has been previously reported that topical application of IMQ also 
induced systemic effects through TLR7 and type I IFN (Grine et al., 
2015). One of the systemic effects observed after the daily treatment 
with IMQ includes splenomegaly in control mice (van der Fits et al., 
2009; Flutter and Nestle, 2013). Recently, it has been described that 
part of the psoriasis-like effects induced by IMQ are due to the oral 
uptake of this substance and are subsequently enhanced by the 
absorption in the intestine (Grine et al., 2016). Considering all this, we 
collected several tissues including spleen and gut at day 7 and 
examined the levels of cytokines that had been measured in the skin.   
 
 
Figure 44. Relative weight spleen/body increased in both genotypes after 
IMQ treatment. Spleens were collected at day 7 of IMQ experiment and 
splenomegaly was determined by the weight ratio of spleen relative to body. 
Mean values ± SD are shown. Post hoc Tukey test #p<0.05; ***p<0.001, n=at 
least 5 per genotype and treatment. Asterisks: significance between treatments 
within each genotype; hashes: significance between genotypes in the same 
treatment group. 
Splenomegaly was determined by the ratio of spleen relative to 
body weight. As expected IMQ induced an enlargement of the spleen 
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in control mice, however, splenomegaly was even more pronounced in 
GILZ-Tg mice (Figure 44).  
 
We next assessed cytokines related with IL-23/Th17 axis in spleen 
and gut. We evaluated also whether the splenomegaly induced by the 
IMQ treatment correlated with changes in the mRNA expression of the 
cytokines up-regulated in skin, as well as possible differences between 
GILZ-Tg and GILZ-Wt mice. Spleen is a lymphoid organ where many 
cells of the immune system are present, which includes T cells (Figure 
44). 
 
Figure 45. Cytokine regulation in spleen after IMQ treatment. Relative 
mRNA levels of the indicated genes were assessed by RT-QPCR in spleen 
collected after IMQ treatment (7d). Mean values ± SD are shown. Post hoc 
Tukey test *p<0.05; **p<0.01; ***p<0.001; n=at least 5 per genotype and 
treatment. Asterisks: significance between treatments within each genotype. 
Il-17f and Il-6 mRNA levels were up-regulated after IMQ treatment 
(Figure 45), whereas no major differences were observed in Il-23 
mRNA levels. Il-17f and Il-6 are induced by IMQ in both GILZ-Wt and 
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GILZ-Tg, suggesting that the overexpression of GILZ in immune cells 
does not trigger an increased activation of the IL-23/Th17 axis. The 
augmented up-regulation of the pro-inflammatory cytokine Il-6 in the 
spleen of IMQ-treated GILZ-Tg mice is consistent with the increased 
splenomegaly relative to GILZ-Wt animals.   
 
Figure 46. Cytokine regulation in gut after IMQ treatment. Relative mRNA 
levels of the indicated genes were assessed by RT-QPCR in gut collected after 
IMQ treatment (7d). Mean values ± SD are shown. Post hoc Tukey test *, # 
p<0.05; ##p<0.01; ***p<0.001; n=at least 5 per genotype and treatment. 
Asterisks: significance between treatments within each genotype; hashes: 
significance between genotypes in the same treatment group. 
In gut, IMQ induced Il-17f mRNA levels in GILZ-Wt mice, whereas 
GILZ-Tg mice showed a significant reduction. Additionally, Il-22 
expression did not change in GILZ-Wt mice in response to IMQ. 
However, we observed a tendency to reduced levels in IMQ-treated 
GILZ-Tg mice. In the case of Il-23, there was a significant decrease in 
GILZ-Wt in response to IMQ, whereas no changes were presented in 
GILZ-Tg mice. 
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The fact that there are no major differences in the levels of 
cytokines between both mouse genotypes in gut and spleen suggests 
that, in these organs, the overexpression of GILZ did not play a major 
role in the more severe phenotype presented in GILZ-Tg after IMQ 
treatment and also that the alterations are skin specific.  
 
Altogether, our data demonstrate that the cytokine profile in the 
skin of IMQ-treated GILZ-Tg mice was different to that of intestine or 
spleen and suggests that in this disease model, GILZ overexpression 
may have a pro-inflammatory role in the skin while playing a protective 
or neutral role in other organs. In addition, the increased levels of 
circulating cytokines in serum in response to IMQ, as reported by other 
groups (Grine et al., 2016), showed no differences among genotypes, 
suggesting that the systemic response is not responsible for the severe 
phenotype observed in the skin of IMQ- treated GILZ-Tg mice.  
 
While the experiments in GILZ-Tg mice were ongoing, it was 
reported that GILZ knockout mice were more susceptible to the IMQ 
model, developing histological psoriasis features, splenomegaly, and 
up-regulation of IL-17A and IL-23 levels (Jones et al., 2015). The fact 
that both gain- and loss-of-function approaches lead to a similar skin 
phenotype and higher susceptibility to psoriasis is apparently 
contradictory. However, several issues must be considered. It is 
important to note that untreated GILZ-deficient mice already displayed 
increased levels of lymph node cells producing IL-17A and IL-22. 
Altogether they demonstrated the importance of GILZ for the regulation 
of Th17-dependent cytokines by T cells and dendritic cells. However, 
it is not clear whether this basal inflammation contributes (and to what 
extent) to the increased susceptibility of GILZ-deficient mice to IMQ. 
Our results, however, showed similar expression of the Il-23, Il-22 
and Il-17 cytokines in the skin of both genotypes in the absence of 
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IMQ and displayed a significantly enhanced increase only after IMQ 
treatment (Figure 41). 
 
Furthermore, the skin alterations in IMQ-treated GILZ-deficient 
mice were not characterized by histopathological assessment. This 
makes difficult to compare whether the excess or deficiency of this 
protein has a similar impact on epidermal proliferation, differentiation, 
etc. The contribution of GILZ-deficient keratinocytes to the reported 
cutaneous phenotype was neither examined. 
 
The fact that the GILZ overexpressing mice and GILZ-deficient 
mice displayed similar phenotypic skin alterations in response to 
IMQ, suggests that GILZ levels must be tightly regulated to effectively 
reduce inflammation, as high or low doses may have pathological 
consequences. Therefore, GILZ levels should be controlled when 
used as an alternative treatment for psoriasis, as it may behave as a 
pro-inflammatory protein in certain tissues, such as the skin. 
 
On the other hand, GILZ has been reported to show a 
compensatory balance with another GC-induced and pro-resolving 
inflammatory protein named Annexin A1 to resolve inflammation 
naturally (Vago et al., 2015). Maybe the excess of GILZ provokes a 
decompensation in the balance with Annexin A1. 
2.3. IMQ-induced psoriasis in GILZ-Tg mice involves 
cutaneous activation of TGF-β1/SMAD2/3 
 
We next investigated other signaling pathways that may contribute 
to the pro-inflammatory action of GILZ in the IMQ model of psoriasis. It 
has been reported that GILZ enhances TGF-β1 signaling by binding to 
and promoting SMAD2/3 phosphorylation and activation of FoxP3 
expression (Bereshchenko et al., 2014). TGF-β1 is the most 
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predominant in several human tissues, including the skin (Han et al., 
2012). 
 
Moreover, mice overexpressing TGF-β1 in keratinocytes 
developed phenotypes and molecular alterations similar to human 
psoriasis, via SMAD2/3-dependent mechanism (Li et al., 2004; Zhang 
et al., 2014). In order to evaluate whether GILZ overexpression 
correlated with an augmented TGF-β1-mediated signaling, we isolated 
the skin, gut and spleen from GILZ-Wt and GILZ-Tg untreated and IMQ-
treated mice and determined the activation status of SMAD2/3 by using 
the relative ratio of phosphorylated (p)- vs total SMAD2/3 expression by 
western blotting.  
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Figure 47. Skin-specific increased activation of SMAD2/SMAD3 by IMQ 
treatment in GILZ-Tg mice. (A) Representative immunoblotting images and 
quantification (below image) of total and phospho(p)-SMAD2/3 expression in 
skin, gut and spleen collected at day 7 of the IMQ experiment. Actin is shown 
as a loading control. The values shown are the mean ± SD; asterisks indicate 
statistically significant differences relative to controls, as assessed using 
Student’s t test (n =31; *p < 0.05). (B) Immunohistochemistry using p-SMAD2/3 
antibody demonstrates activation of TGF-β1 signaling mediators in the 
epidermis and dermis of IMQ-treated GILZ-Tg and GILZ-Wt mice. Bar: 50 µm.  
Immunoblotting showed an increased constitutive activation of 
SMAD2/3 (Figure 47A) in GILZ-Tg mouse skin. In addition, IMQ 
induced SMAD2/3 activation in both genotypes, although the increase 
was much higher in GILZ-Tg mice (Figure 47A). However, SMAD2/3 
activity was unchanged in gut and spleen of GILZ-Tg vs GILZ-Wt mice, 
suggesting a specific activation of this signaling pathway in skin. 
Furthermore, we localized p-SMAD2/3 in epidermis and dermis, but the 
expression was mostly found in the epidermal keratinocytes (Figure 
47B).  
 
To evaluate whether the observed activation of TGF-β1/SMAD 
signaling pathway was due to its transcriptional up-regulation, we 
measured Tgfβ1 mRNA levels in the skin of untreated or IMQ-treated 
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GILZ-Wt and GILZ-Tg mice at day 7. However, we found no changes 
between both treated and untreated genotypes in skin and spleen.  
 
Figure 48. No changes in Tgfβ1 mRNA levels in skin of GILZ-Tg vs GILZ-
Wt mice. Relative mRNA levels of Tgfβ1 were assessed by RT-QPCR in skin 
collected after IMQ treatment (7d). Mean values ± SD are shown. n= 6 per 
genotype and treatment.  
Although we cannot rule out that Tgfβ1 mRNA is induced in the 
skin by IMQ at earlier time-points, our data suggest that GILZ 
overexpression modulates TGF-β1 activity without altering its mRNA 
levels at day 7 of IMQ treatment.  
 
TGF-β1 has been reported to impair the GC-induced 
transcriptional activation in human bronchial epithelial cells, reducing 
GILZ expression through ALK5-SMAD2/3 (Keenan et al., 2014). This is 
consistent with our results in IMQ-treated GILZ-Wt skin, where Gilz 
mRNA levels are decreased maybe due to the activation of SMAD2/3. 
The fact that an increased activation of SMAD2/3 in IMQ-treated      
GILZ-Tg mice did not reduce the Gilz mRNA levels could be due to the 
lack of regulatory sequences in the Gilz transgene. 
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2.4. Contribution of immune cells and keratinocytes to 
psoriasis-like alterations in GILZ-Tg mice 
IMQ stimulates dendritic cells to produce IL-23, which activates 
immune cells in the lymph nodes and induces the expression of IL-17A 
(Van der Fits et al., 2009), thus activating signaling pathways in other 
cells (Figure 49). 
 
We wondered whether immune cells in lymph nodes could 
contribute to the more severe skin phenotype in GILZ-Tg mice after IMQ 
treatment.  
 
Figure 49. Scheme of relative contribution of immune cells and 
keratinocytes after IMQ treatment. IMQ induces the expression of IL-23 in 
dendritic cells, which stimulates T cells to secrete IL-17A, enhancing the 
subsequent activation of signaling pathways in several cell types and the up-
regulation of the psoriasis marker S100a8 in keratinocytes.  
To address this question we topically applied IMQ on mouse ear 
and isolated the cells from brachial lymph nodes and cultured them. 
Subsequently, cultured cells were re-stimulated with Aldara (10 μg/ml) 
for 3 days and then IL-17A expression was measured in the 
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supernatant. We found that IMQ induced the expression of IL-17A in 
lymph node cells. However, this increase was not significantly different 
in GILZ-Tg compared to GILZ-Wt cells after IMQ treatment (Figure 50).  
 
Figure 50. IL-17A is similarly up-regulated by IMQ in lymph node cells 
from GILZ-Tg and GILZ-WT mice. Immune cells were isolated from brachial 
lymph nodes of either vehicle- or IMQ-treated GILZ-Wt and GILZ-Tg mice after 
7 d. Then lymph node cells were cultured and treated with Aldara 10 μg/ml. 
After 3 days, IL-17A was measured in the supernatant by Luminex technology. 
n = 3 mice per genotype and treatment. Mean values ± SD are shown. Post 
hoc Tukey test ***p<0.001. 
The IL-17A is secreted by immune cells and activates other cells 
including keratinocytes and induces the expression of the psoriatic 
marker S100a8 (Ha et al., 2014; Figure 49). To assess the specific 
contribution of keratinocytes, we transfected an established mouse 
keratinocyte cell line with an empty vector or GILZ; then cells were 
treated with vehicle or IL-17A (Figure 51). IL-17A increased S100a8 
mRNA levels by 2-fold in the control keratinocytes. It is worth noting that 
in GILZ overexpressing keratinocytes S100a8 expression was 
significantly up-regulated compared with the control keratinocytes 
(Figure 51).  
Results and Discussion  
 
124 
 
 
Figure 51. Increased up-regulation of S100a8 mRNA levels in GILZ-
transfected keratinocytes. Adult immortalized mouse keratinocytes were 
transfected with an empty vector or GILZ; then cells were treated with vehicle 
or IL-17A (100 ng/mL) for 24 h and relative mRNA levels of S100a8 were 
assessed by RT-QPCR. Mean values ± SD are shown. n=at least 6 
independent replicates per transfection and treatment. Post hoc Tukey test 
#p<0.05; ##p<0.01; ***p<0.001. Asterisks: significance between treatments 
within each genotype; hashes: significance between genotypes in the same 
treatment group.  
Next, we used cultured keratinocytes that were transfected with 
empty vector or GILZ and treated with vehicle or TGF-β1, and 
performed assays using a SMAD-luciferase reporter. In response to 
TGF-β1 (1 ng/µL, 20 h), we detected 26- to 31-fold activation of the 
SMAD-luc reporter (Figure 52, empty and GILZ vectors, respectively). 
Although GILZ overexpressing cells presented a tendency to increase 
activation of SMAD-luc activity after TGF-β1 treatment, it did not reach 
statistical significance compared with keratinocytes transfected with 
empty vector. The increased trend of SMAD activation observed in vitro 
in GILZ-transfected keratinocytes is consistent with our previous results 
in GILZ-Tg relative to GILZ-Wt skin. 
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Figure 52. GILZ overexpression in cultured keratinocytes does not 
significantly increase the TGF-β1–induced SMAD activity. Cultured control 
or GILZ-overexpressing keratinocytes were treated with TGF-β1 (1 ng/µL, 20 
h) and activation of a SMAD-luc reporter was determined. Mean values ± SD 
are shown. n=3 independent experiments.Post hoc Tukey test ***p<0.001. 
Altogether our data demonstrated that the overexpression of GILZ 
exerted pro-inflammatory actions specifically in skin. Additionally, the in 
vitro data suggest that keratinocytes but not immune cells isolated from 
lymph nodes contributed to an altered skin phenotype in IMQ 
experiment in the presence of higher amounts of GILZ.  
Finally, we propose a schematic model to summarize the effects 
of GILZ overexpression in IMQ-induced psoriasis mouse model 
(Figure 53).  
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Figure 53. Consequences of generalized GILZ overexpression in the 
IMQ-induced mouse psoriasiform skin lesions. During the protocol of 
IMQ-induced mouse psoriasis, the generalized overexpression of GILZ led 
to the enhancement of pro-inflammatory cytokines (both systemically and in 
skin lesions), skin-specific overactivation of the TGF-β1/SMAD2/3 pathway, 
resulting in histopathological and molecular psoriasis-like alterations in 
GILZ-Tg mice. 
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Part I: Analysis of the functional cooperation of the 
glucocorticoid (GC) receptor (GR) and Krüppel-like 
factor (KLF) 4 in the regulation of gene expression in 
epidermal keratinocytes 
1. GC primary transcriptional targets previously identified in ChIP-seq 
assays performed in cultured mouse keratinocytes contained 
overrepresented canonical binding motifs for GR (64%), AP-1 (28%) 
and KLF (43%), suggesting the importance of these TFs in the early 
response of epidermal keratinocytes to GCs.  
 
2. GR and KLF4 cooperate to regulate the transcription of the anti-
inflammatory genes Gilz and Zfp36 by binding at adjacent genomic 
regulatory regions in response to GCs in epidermal keratinocytes, as 
well as during terminal differentiation, as demonstrated by gene 
expression and ChIP-QPCR analyses in cultured cells. 
3. KLF4 is recruited to the genomic regulatory sequences of Gilz and 
Zfp36 after GC treatment in keratinocytes in a GR-dependent manner. 
GR is also important for the induction of Klf4, Gilz and Zfp36 during 
keratinocyte differentiation. 
 
4. The presence of GR is necessary to terminal differentiation 
commitment in epidermal keratinocytes, which correlates with a 
downregulation of Trp63 isoforms due to transcriptional regulation of 
both ΔNp63 and TAp63, which ultimately results in Klf4 up-regulation. 
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Part II: Functional analysis of GILZ in transgenic mice 
with generalized overexpression: implications in 
psoriasis. 
1. In the IMQ-induced psoriasis mouse model, GILZ overexpression 
promotes increased susceptibility to develop more severe psoriasiform 
skin lesions, as shown by the histopathological (epidermal thickening 
with immune infiltrates, abnormal differentiation) and molecular 
alterations (IL-23/Th17 axis). 
 
2. Overexpression of GILZ correlates with skin-specific overactivation 
of TGF-β1/SMAD signaling, which contributes to the increased 
susceptibility to psoriasis.  
 
3. Our data indicate that the pro-inflammatory actions of GILZ are 
specific to the skin as other organs such as the spleen did not show 
increased levels of Th17-dependent cytokines relative to controls and 
no significant difference in the circulating cytokines was observed. 
 
4. Cultured keratinocytes overexpressing GILZ show significantly 
higher up-regulation of the psoriasis marker S100a8 in response to        
IL-17 and an increased trend of TGF-β1-induced SMAD activation. Our 
results indicate that the overexpression of GILZ in keratinocytes versus 
immune cells contribute differently to the susceptibility to psoriasis. 
 
 
 
  
 
 
 
Conclusiones 
 
 
  
 
Conclusiones 
 
133 
 
Parte I: Análisis de la cooperación funcional del 
receptor de glucocorticoides (GR) y Krüppel-like factor 
(KLF) 4 en la regulación de la expresión génica en 
queratinocitos epidérmicos 
1. Las dianas transcripcionales primarias de glucocorticoides (GC) 
previamente idenificadas en experimentos de ChIP-seq realizados en 
queratinocitos en cultivo de ratón contenían una sobrerepresentación 
de motivos de unión canónicos para GR (64%), AP-1 (28%) y KLF 
(43%), lo que sugiere la importancia de estos factores de transcripción 
en la respuesta temprana a GCs en este tipo celular. 
 
2. GR y KLF4 cooperan para regular la transcripción de los genes 
antiinflamatorios Gilz y Zfp36 mediante la unión a las regiones 
reguladoras genómicas adyacentes en respuesta a GCs en 
queratinocitos epidérmicos, así como durante la diferenciación 
terminal, como se demuestra por la expresión génica y los análisis de 
ChIP-QPCR en células en cultivo. 
3. KLF4 se recluta a las secuencias reguladoras genómicas de Gilz y 
Zfp36 después del tratamiento con GC en queratinocitos de una 
manera dependiente de GR. Además, GR es importante para la 
inducción de Klf4, Gilz and Zfp36 durante la diferenciación de 
queratinocitos. 
4. La presencia de GR es necesaria para el compromiso de la 
diferenciación terminal en queratinocitos epidérmicos, lo que se 
correlaciona con una regulación negativa de las isoformas Trp63 
debido a la regulación transcripcional tanto de ΔNp63 como de TAp63, 
que finalmente da lugar a una regulación positiva de Klf4. 
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Parte II: Análisis funcional de GILZ en ratones 
transgénicos con sobreexpresión generalizada: 
implicaciones en psoriasis. 
1. En el modelo de psoriasis en ratón inducido por IMQ, la 
sobreexpresión de GILZ promueve una mayor susceptibilidad a 
desarrollar lesiones cutáneas psoriasiformes más severas, como se 
demuestra por las alteraciones histopatológicas (engrosamiento 
epidérmico con infiltrados de células inmunes, diferenciación anormal) 
y alteraciones moleculares (eje IL-23/Th17). 
2. La sobreexpresión de GILZ se correlaciona con la sobreactivación 
de la señalización de TGF-β1/SMAD específica de la piel, lo que 
contribuye a la susceptibilidad aumentada en la psoriasis. 
 
3. Nuestros datos indican que las acciones pro-inflamatorias de GILZ 
son específicas de la piel, ya que otros órganos tales como el bazo no 
mostraron niveles aumentados de citocinas dependientes de Th17 en 
comparación con los controles y no se observó ninguna diferencia 
significativa en las citocinas circulantes. 
4. Los queratinocitos en cultivo que sobreexpresan GILZ muestran una 
aumento significativamente mayor del marcador de psoriasis S100a8 
en respuesta a IL-17 y una tendencia aumentada de la activación de 
SMAD inducida por TGF-β1. Nuestros resultados indican que la 
sobreexpresión de GILZ en queratinocitos frente a células inmunitarias 
contribuyen de manera diferente a la susceptibilidad de la psoriasis. 
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